Inflammatory Bowel Disease: UK NHS Treatments & Clinical Trials
Independent directory of medicines authorised by the MHRA, NHS funding decisions by NICE, and actively recruiting clinical trials across UK hospital sites. Designed for patients, clinicians, and patient support organisations.
Approved NHS Treatments & NICE Guidance
(58 medicines)Medicines licensed by the UK Medicines and Healthcare products Regulatory Agency (MHRA) and evaluated for NHS funding by the National Institute for Health and Care Excellence (NICE). NICE recommendations define exact patient eligibility rules under which the NHS covers therapy.
No active NICE technology appraisal decision recorded for this condition.
No active NICE technology appraisal decision recorded for this condition.
No active NICE technology appraisal decision recorded for this condition.
Mesalamine
No active NICE technology appraisal decision recorded for this condition.
No active NICE technology appraisal decision recorded for this condition.
No active NICE technology appraisal decision recorded for this condition.
No active NICE technology appraisal decision recorded for this condition.
No active NICE technology appraisal decision recorded for this condition.
No active NICE technology appraisal decision recorded for this condition.
Tyruko (natalizumab-sztn)
Crohn's Disease
Natalizumab biosimilar authorised in the UK exclusively for multiple sclerosis; not licensed or funded for Crohn's disease.
adalimumab · Humira
Adults and paediatric patients with moderately to severely active CD or UC who have had an inadequate response to conventional therapy
Ulcerative Colitis
1.1 Infliximab, adalimumab and golimumab are recommended, within their marketing authorisations, as options for treating moderately to severely active ulcerative colitis in adults whose disease has responded inadequately to conventional therapy including corticosteroids and mercaptopurine or azathioprine, or who cannot tolerate, or have medical contraindications for, such therapies.
Crohn's Disease
1.1 Infliximab and adalimumab, within their licensed indications, are recommended as treatment options for adults with severe active Crohn's disease (see section 1.6) whose disease has not responded to conventional therapy (including immunosuppressive and/or corticosteroid treatments), or who are intolerant of or have contraindications to conventional therapy.
No active NICE technology appraisal decision recorded for this condition.
No active NICE technology appraisal decision recorded for this condition.
No active NICE technology appraisal decision recorded for this condition.
adalimumab-adbm (Cyltezo)
No active NICE technology appraisal decision recorded for this condition.
No active NICE technology appraisal decision recorded for this condition.
No active NICE technology appraisal decision recorded for this condition.
No active NICE technology appraisal decision recorded for this condition.
No active NICE technology appraisal decision recorded for this condition.
No active NICE technology appraisal decision recorded for this condition.
No active NICE technology appraisal decision recorded for this condition.
No active NICE technology appraisal decision recorded for this condition.
No active NICE technology appraisal decision recorded for this condition.
No active NICE technology appraisal decision recorded for this condition.
No active NICE technology appraisal decision recorded for this condition.
certolizumab pegol · Cimzia
Crohn's Disease
Not authorised by MHRA or recommended by NICE for Crohn's disease in the UK.
etrasimod · Velsipity
Patients aged 16 years and older with moderately to severely active UC who have had an inadequate response, lost response, or were intolerant to conventional therapy or a biologic agent
Ulcerative Colitis
1.1 Etrasimod is recommended, within its marketing authorisation, as an option for moderately to severely active ulcerative colitis in people aged 16 years and over when: conventional or biological treatments cannot be tolerated or the condition has not responded well enough, or lost response to treatment.
Adults with moderately to severely active UC who have had an inadequate response to conventional therapy
Ulcerative Colitis
1.1 Infliximab, adalimumab and golimumab are recommended, within their marketing authorisations, as options for treating moderately to severely active ulcerative colitis in adults whose disease has responded inadequately to conventional therapy including corticosteroids and mercaptopurine or azathioprine, or who cannot tolerate, or have medical contraindications for, such therapies.
guselkumab · Tremfya
Adult patients with moderately to severely active UC who have had an inadequate response, lost response, or were intolerant to conventional therapy or a biologic
Ulcerative Colitis
1.1 Guselkumab can be used as an option for treating moderately to severely active ulcerative colitis in adults when: a conventional treatment, biological treatment or Janus kinase (JAK) inhibitor: has not worked (that is, the condition has not responded well enough or lost response to treatment), or cannot be
No active NICE technology appraisal decision recorded for this condition.
No active NICE technology appraisal decision recorded for this condition.
infliximab · Remicade
Adults and paediatric patients with moderately to severely active CD or UC
Ulcerative Colitis
1.1 Infliximab, adalimumab and golimumab are recommended, within their marketing authorisations, as options for treating moderately to severely active ulcerative colitis in adults whose disease has responded inadequately to conventional therapy including corticosteroids and mercaptopurine or azathioprine, or who cannot tolerate, or have medical contraindications for, such therapies.
Crohn's Disease
1.1 Infliximab and adalimumab, within their licensed indications, are recommended as treatment options for adults with severe active Crohn's disease (see section 1.6) whose disease has not responded to conventional therapy (including immunosuppressive and/or corticosteroid treatments), or who are intolerant of or have contraindications to conventional therapy.
No active NICE technology appraisal decision recorded for this condition.
No active NICE technology appraisal decision recorded for this condition.
No active NICE technology appraisal decision recorded for this condition.
No active NICE technology appraisal decision recorded for this condition.
infliximab-qbtx (Ixifi)
No active NICE technology appraisal decision recorded for this condition.
No active NICE technology appraisal decision recorded for this condition.
No active NICE technology appraisal decision recorded for this condition.
No active NICE technology appraisal decision recorded for this condition.
No active NICE technology appraisal decision recorded for this condition.
No active NICE technology appraisal decision recorded for this condition.
mirikizumab · Omvoh
Adult patients with moderately to severely active UC or CD who have had an inadequate response, lost response, or were intolerant to conventional therapy or a biologic therapy
Ulcerative Colitis
1.1 Mirikizumab is recommended as an option for treating moderately to severely active ulcerative colitis in adults when conventional or biological treatment cannot be tolerated, or the condition has not responded well enough or lost response to treatment, only if: a tumour necrosis factor (TNF)‑alpha inhibitor has not
Crohn's Disease
1.1 Mirikizumab can be used as an option to treat moderately to severely active Crohn's disease in adults, only if: the disease has not responded well enough or stopped responding to a previous biological treatment, or a previous biological treatment was not tolerated, or tumour necrosis factor (TNF)-alpha inhibitors are not suitable.
natalizumab · Tysabri
Crohn's Disease
Not licensed by MHRA or funded by NICE for Crohn's disease in the UK due to risk of progressive multifocal leukoencephalopathy (PML).
No active NICE technology appraisal decision recorded for this condition.
ozanimod · Zeposia
Adult patients with moderately to severely active UC who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biologic agent
Ulcerative Colitis
1.1 Ozanimod is recommended as an option for treating moderately to severely active ulcerative colitis in adults, only if: conventional treatment cannot be tolerated or is not working well enough and infliximab is not suitable, or biological treatment cannot be tolerated or is not working well enough, and the company
risankizumab · Skyrizi
Adult patients with moderately to severely active CD or UC who have had an inadequate response to, lost response to, or were intolerant to conventional therapy or a biologic therapy
Ulcerative Colitis
1.1 Risankizumab is recommended as an option for treating moderately to severely active ulcerative colitis in adults when conventional or biological treatment cannot be tolerated, or the condition has not responded well enough or has lost response to treatment, only if: a tumour necrosis factor (TNF)-alpha inhibitor:
Crohn's Disease
1.1 Risankizumab is recommended as an option for treating moderately to severely active Crohn's disease in people 16 years and over, only if: the disease has not responded well enough or lost response to a previous biological treatment, or a previous biological treatment was not tolerated, or tumour necrosis factor (TNF)-alpha inhibitors are not suitable.
tofacitinib · Xeljanz
Adult patients with moderately to severely active UC who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biologic agent
Ulcerative Colitis
1.1 Tofacitinib is recommended, within its marketing authorisation, as an option for treating moderately to severely active ulcerative colitis in adults when conventional therapy or a biological agent cannot be tolerated or the disease has responded inadequately or lost response to treatment.
upadacitinib · Rinvoq
Adult patients with moderately to severely active UC or CD who have had an inadequate response, lost response or were intolerant to conventional therapy or a biologic agent
Ulcerative Colitis
1.1 Upadacitinib is recommended, within its marketing authorisation, as an option for treating moderately to severely active ulcerative colitis in adults: when conventional or biological treatment cannot be tolerated, or if the condition has not responded well enough or has stopped responding to these treatments, and
Crohn's Disease
1.1 Upadacitinib is recommended as an option for treating moderately to severely active Crohn's disease in adults, only if: the disease has not responded well enough or lost response to a previous biological treatment or a previous biological treatment was not tolerated or tumour necrosis factor (TNF)-alpha inhibitors are contraindicated.
ustekinumab · Stelara
Adult patients with moderately to severely active CD or UC who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a TNF antagonist
Ulcerative Colitis
1.1 Ustekinumab is recommended as an option for treating moderately to severely active ulcerative colitis in adults when conventional therapy or a biological agent cannot be tolerated, or the disease has responded inadequately or lost response to treatment, only if: a tumour necrosis factor‑alpha inhibitor has failed
Crohn's Disease
1.1 Ustekinumab is recommended, within its marketing authorisation, as an option for treating moderately to severely active Crohn's disease, that is, for adults who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a TNF‑alpha inhibitor or have medical
No active NICE technology appraisal decision recorded for this condition.
No active NICE technology appraisal decision recorded for this condition.
No active NICE technology appraisal decision recorded for this condition.
No active NICE technology appraisal decision recorded for this condition.
No active NICE technology appraisal decision recorded for this condition.
No active NICE technology appraisal decision recorded for this condition.
No active NICE technology appraisal decision recorded for this condition.
vedolizumab · Entyvio
Adult patients with moderately to severely active UC or CD who had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a TNF antagonist
Crohn's Disease
1.1 Vedolizumab is recommended as an option for treating moderately to severely active Crohn's disease only if: a tumour necrosis factor‑alpha inhibitor has failed (that is, the disease has responded inadequately or has lost response to treatment) or a tumour necrosis factor‑alpha inhibitor cannot be tolerated or is contraindicated.
Ulcerative Colitis
1.1 Vedolizumab is recommended, within its marketing authorisation, as an option for treating moderately to severely active ulcerative colitis in adults only if the company provides vedolizumab with the discount agreed in the patient access scheme.
UK IBD Clinical Trials Finder
(57 actively recruiting)Clinical trials with active research sites across NHS trusts and hospitals in the United Kingdom. Studies listed as "Recruiting" or "Enrolling" are actively seeking eligible patient participants.
Open for Recruitment (57)
Extension Study of Long-term Safety and Efficacy of Tulisokibart in Participants With Crohn's Disease or Ulcerative Colitis (MK-7240-011)
📍 London · Prescot (2 sites)Est. primary completion: 2037-12-17A Study to Learn More About How Risankizumab Works in Young Participants With Ulcerative Colitis
📍 Cambridge · Sheffield · Liverpool (3 sites)Est. primary completion: 2034-07A Study of Vedolizumab in Children With Ulcerative Colitis (UC) or Crohn's Disease (CD)
📍 London · Cardiff · Birmingham · Manchester (4 sites)Est. primary completion: 2033-02-07A Study Investigating Oral Ozanimod (RPC1063) in Pediatric Participants With Moderate to Severe Active Ulcerative Colitis
📍 Birmingham · London (2 sites)Est. primary completion: 2032-07-12A Long-term Extension (LTE) Study of Guselkumab in Pediatric Participants
📍 Sheffield · Stoke-on-Trent (2 sites)Est. primary completion: 2031-12-12Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)
📍 London · Southampton · Salford · Bristol · High Wycombe · Kirkcaldy (6 sites)Est. primary completion: 2031-01-16Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)
📍 London · Southampton · Salford · Bristol · High Wycombe · Kirkcaldy (6 sites)Est. primary completion: 2031-01-16A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn's Disease (SHINE-ON)
📍 London · Oxford · Sheffield (3 sites)Est. primary completion: 2030-12A Study of How the Medicine Called "Etrasimod" Works in Children With the Gut Disease Called Ulcerative Colitis
📍 London · Bristol · Liverpool · Sheffield (4 sites)Est. primary completion: 2030-09-08A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis
📍 Plymouth · London · Southampton · Glasgow · Manchester · Newcastle upon Tyne (6 sites)Est. primary completion: 2030-07A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis
📍 Plymouth · London · Southampton · Glasgow · Manchester · Newcastle upon Tyne (6 sites)Est. primary completion: 2030-07A Study to Assess the Pharmacokinetics, Effectiveness and Safety of Afimkibart for Induction and Maintenance Therapy in Children With Moderately to Severely Active Crohn's Disease
📍 Sheffield (1 site)Est. primary completion: 2030-05-31Adalimumab Dose Adjustment for Pediatric Uveitis Treatment Trial
📍 Bristol · Leicester · Liverpool · London · Manchester · Newcastle upon Tyne · Norwich · Sheffield (8 sites)Est. primary completion: 2030-05A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata
📍 High Wycombe · Brighton · Gloucester · London · Oxford · Harrow · Salford (7 sites)Est. primary completion: 2030-04A Study to Evaluate the Pharmacokinetics, Safety and Efficacy of Afimkibart (RO7790121) in Children With Moderately to Severely Active Ulcerative Colitis
📍 Birmingham · Cambridge · Sheffield (3 sites)Est. primary completion: 2030-03-31Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease
📍 Edinburgh · Glasgow · London · Oxford · Coventry · Wolverhampton · Bristol · Cardiff · Newcastle upon Tyne (9 sites)Est. primary completion: 2030-01Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease
📍 Edinburgh · Glasgow · London · Oxford · Coventry · Wolverhampton · Bristol · Cardiff · Newcastle upon Tyne (9 sites)Est. primary completion: 2030-01Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease
📍 Edinburgh · Glasgow · London · Oxford · Coventry · Wolverhampton · Bristol · Cardiff · Newcastle upon Tyne (9 sites)Est. primary completion: 2030-01- NCT06548542 ↗ABBV-8736
Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease
📍 Edinburgh · Glasgow · London · Oxford · Coventry · Wolverhampton · Bristol · Cardiff · Newcastle upon Tyne (9 sites)Est. primary completion: 2030-01 Study of Oral Upadacitinib and Subcutaneous/Intravenous Tocilizumab to Evaluate Change in Disease Activity, Adverse Events and How Drug Moves Through the Body of Pediatric and Adolescent Participants With Active Systemic Juvenile Idiopathic Arthritis.
📍 London (1 site)Est. primary completion: 2029-06An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
📍 London (1 site)Est. primary completion: 2029-05-14A Study to Assess Adverse Events, Change in Disease Activity, and How Intravenous and Subcutaneous Risankizumab Moves Through the Body of Pediatric Participants With Moderately to Severely Active Crohn's Disease
📍 Sheffield · London · Birmingham (3 sites)Est. primary completion: 2029-04VECTORS - A Study to Evaluate Transmural Healing as a Treatment Target in Crohn's Disease
📍 Nottingham · Harrow · Edinburgh · London (4 sites)Est. primary completion: 2029-01-03A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease
📍 Cambridge · Harrow · Liverpool · London · Newcastle upon Tyne · North Shields · Nottingham (7 sites)Est. primary completion: 2028-12-31A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease
📍 Bristol · Bury · Llanrhystud · London · Stockport (5 sites)Est. primary completion: 2028-12-31A Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn's Disease
📍 Greater London · Iselworth · London · Norwich · Wolverhampton (5 sites)Est. primary completion: 2028-11-15A Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn's Disease
📍 Greater London · Iselworth · London · Norwich · Wolverhampton (5 sites)Est. primary completion: 2028-11-15A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)
📍 Cambridge · Exeter · Doncaster · Huddersfield · London · Southampton · Oxford · Bristol · West Midlands (9 sites)Est. primary completion: 2028-10-30A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease
📍 Birmingham · Cambridge · Glasgow · Greater Manchester · London · Rainhill · Stockport (7 sites)Est. primary completion: 2028-09-19A Study Evaluating the Effects of Filgotinib in Children and Teenagers With Ulcerative Colitis
📍 Bristol · Glasgow · Liverpool · London · Newcastle · Sheffield (6 sites)Est. primary completion: 2028-06Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study
📍 Bristol · Dundee · Exeter · London (4 sites)Est. primary completion: 2028-04Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study
📍 Bristol · Dundee · Exeter · London (4 sites)Est. primary completion: 2028-04A Protocol of Icotrokinra Therapy in Adult and Adolescent Participants With Moderately to Severely Active Ulcerative Colitis
📍 Cambridge · Edinburgh · Greater Manchester · London · Rainhill · Sheffield · Stockport (7 sites)Est. primary completion: 2028-01-14A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease
📍 Edinburgh · Headington · London · Manchester · Sheffield · Whitechapel (6 sites)Est. primary completion: 2027-12OLE Study With Filgotinib in JIA
📍 London (1 site)Est. primary completion: 2027-12Natalizumab for the Treatment of People With Inflammatory Demyelination Suggestive of Multiple Sclerosis, or Definite Multiple Sclerosis, at First Presentation (AttackMS)
📍 London (1 site)Est. primary completion: 2027-10-31Natalizumab for the Treatment of People With Inflammatory Demyelination Suggestive of Multiple Sclerosis, or Definite Multiple Sclerosis, at First Presentation (AttackMS)
📍 London (1 site)Est. primary completion: 2027-10-31A Study to Evaluate Efficacy and Safety of MK-8690 in Participants With Moderately to Severely Active Ulcerative Colitis (MK-8690-002)
📍 Bury · Huddersfield (2 sites)Est. primary completion: 2027-10-28A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Crohn's Disease
📍 Glasgow · London · Manchester · Oxford · Sheffield (5 sites)Est. primary completion: 2027-10-27A Study of Vedolizumab in Children and Teenagers With Moderate to Severe Crohn's Disease (CD)
📍 London · Cardiff · Birmingham · Manchester (4 sites)Est. primary completion: 2027-09-13A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics (PK) of RO7837195 in Participants With Moderately to Severely Active Ulcerative Colitis (UC)
📍 London · Liverpool · Oxford · Cambridge (4 sites)Est. primary completion: 2027-08-25An Early-Stage Study in Multiple Clinics of How Afimkibart May Affect the Body's Processing of Medicines That Rely on Cytochrome P450 Enzymes in Participants With Ulcerative Colitis
📍 Liverpool · London · Newcastle upon Tyne (3 sites)Est. primary completion: 2027-07-31A Clinical Study of Tulisokibart (MK-7240) to Treat Radiographic Axial Spondyloarthritis (MK-7240-013)
📍 Norwich · Bath · Barnet · Bradford (4 sites)Est. primary completion: 2027-06-15A Study of Vedolizumab With and Without Upadacitinib in Adults With Crohn's Disease
📍 London · Edinburgh · Glasgow (3 sites)Est. primary completion: 2027-06-08A Study of Vedolizumab With and Without Upadacitinib in Adults With Crohn's Disease
📍 London · Edinburgh · Glasgow (3 sites)Est. primary completion: 2027-06-08Crohn's Disease: Efficacy, Safety, and Pharmacokinetics of Upadacitinib in Pediatric Subjects With Moderately to Severely Active Crohn's Disease
📍 Cambridge · Sheffield · London · Norwich · Edinburgh (5 sites)Est. primary completion: 2027-06Safety, Tolerability, Pharmacokinetics, and Efficacy of Filgotinib for the Treatment of Polyarticular-course Juvenile Idiopathic Arthritis in Children and Adolescents
📍 Bristol · Leicester · Nottingham (3 sites)Est. primary completion: 2027-06A Study to Assess the Efficacy and Safety of RO7790121 in Participants With Moderate to Severe Rheumatoid Arthritis Who Have Not Responded to or Who Cannot Tolerate Tumor Necrosis Factor (TNF) and/or Janus Kinase (JAK Inhibitors)
📍 Leicester · Doncaster · Newcastle upon Tyne · Barnet (4 sites)Est. primary completion: 2027-04-19A Study to Evaluate the Efficacy and Safety of Icotrokinra (JNJ-77242113) in Biologic-experienced and Biologic-naive Participants With Active Psoriatic Arthritis
📍 Barnet · Basingstoke · Christchurch · Edinburgh · Glasgow · Hereford · Larbert · Staffordshire · Torquay · Wolverhampton · Wrexham (11 sites)Est. primary completion: 2027-02-10Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis and Anti-TNFα Inadequate Response
📍 Westcliff-on-Sea · Barnet · Leeds · Wolverhampton (4 sites)Est. primary completion: 2027-01-15Randomised Treatment of Acute Pancreatitis With Infliximab: Double-blind, Placebo-controlled, Multi-centre Trial (RAPID-I)
📍 Aberdeen · Cardiff · Truro · Exeter · London · Liverpool · Whiston · Nottingham · Oxford · Leeds · Upton (11 sites)Est. primary completion: 2026-12-15Efficacy and Safety of Infliximab for Immune Checkpoint Inhibitor Induced Colitis
📍 London (1 site)Est. primary completion: 2026-09Efficacy and Safety of Infliximab for Immune Checkpoint Inhibitor Induced Colitis
📍 London (1 site)Est. primary completion: 2026-09A Study to Assess Adverse Events, Change in Disease Activity, and How the Drug Moves Through the Body in Children With Juvenile Psoriatic Arthritis (jPsA) Receiving Subcutaneously Injected Risankizumab or Adalimumab
📍 Sheffield · Bristol · Liverpool (3 sites)Est. primary completion: 2026-09A Study to Assess Adverse Events, Change in Disease Activity, and How the Drug Moves Through the Body in Children With Juvenile Psoriatic Arthritis (jPsA) Receiving Subcutaneously Injected Risankizumab or Adalimumab
📍 Sheffield · Bristol · Liverpool (3 sites)Est. primary completion: 2026-09Study to Evaluate Pharmacokinetics, Relative Bioavailability, Palatability of Obefazimod Minitablet Formulation
📍 Nottingham (1 site)Est. primary completion: 2026-09Drug-Drug Interaction (DDI) Study of Leramistat in Healthy Adult Subjects
📍 Belfast (1 site)Est. primary completion: 2024-09-30
View 438 closed or completed UK research studies
An Extension Study for Treatment of Moderately to Severely Active Ulcerative Colitis
Yeovil · LondonCompleted 2029-06-19
A Study of the Efficacy and Safety of Risankizumab in Participants With Crohn's Disease
Cambridge · Exeter · Hull · Edinburgh · Glasgow · London · Manchester · Oxford · Barnsley · Chertsey · Leeds · Birmingham · Huddersfield · Newcastle upon TyneCompleted 2029-02
A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Ulcerative Colitis
Cambridge · Exeter · Edinburgh · London · Southampton · Barnsley · Liverpool · Newcastle upon TyneCompleted 2028-09
Study to Assess Adverse Events, Change in Disease Activity, and How Oral Upadacitinib Moves Through the Body of Pediatric Participants With Moderately to Severely Active Ulcerative Colitis.
Sheffield · London · Southampton · BirminghamCompleted 2028-08
Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 6 and 17 Years With Moderate to Severe Plaque Psoriasis Treated With Subcutaneous (SC) Injection of Risankizumab Who Have Completed Participation in Study M19-977
Exeter · Plymouth · LondonCompleted 2028-04
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy
London · Southampton · Coventry · Leeds · Bristol · SalfordCompleted 2028-03
Study Comparing Intravenous (IV)/Subcutaneous (SC) Risankizumab to IV/SC Ustekinumab to Assess Change in Crohn's Disease Activity Index (CDAI) in Adult Participants With Moderate to Severe Crohn's Disease (CD)
Cambridge · Exeter · Edinburgh · London · Southampton · Stevenage · Glasgow · Nottingham · Oxford · Belfast · Huddersfield · Newcastle upon Tyne · Salford · StirlingCompleted 2028-02
Study Comparing Intravenous (IV)/Subcutaneous (SC) Risankizumab to IV/SC Ustekinumab to Assess Change in Crohn's Disease Activity Index (CDAI) in Adult Participants With Moderate to Severe Crohn's Disease (CD)
Cambridge · Exeter · Edinburgh · London · Southampton · Stevenage · Glasgow · Nottingham · Oxford · Belfast · Huddersfield · Newcastle upon Tyne · Salford · StirlingCompleted 2028-02
Effect of Proactive Therapeutic Drug Monitoring on Maintenance of Sustained Disease Control in Adults With Rheumatoid Arthritis on a Subcutaneous TNF Inhibitor: The Rheumatoid Arthritis Therapeutic DRUg Monitoring Trial (RA-DRUM)
LondonCompleted 2027-12-31
A Long-term Extension Study of Ustekinumab in Pediatric Participants
Birmingham · Cambridge · London · Sheffield · SouthamptonCompleted 2027-09-29
A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn's Disease Who Completed the Studies M14-431 or M14-433
Bath · Warrington · London · Taunton · Prescot · Belfast · Birmingham · Dudley · Harrow · Newcastle upon Tyne · Stockport · WolverhamptonCompleted 2027-09
A Study to Assess Adverse Events and Change in Disease Activity From Intravenous (IV) and Subcutaneous (SC) Lutikizumab in Adult Participants With Active Ulcerative Colitis
Cambridge · Glasgow · London · OxfordCompleted 2027-09
A Study to Assess Adverse Events and Change in Disease Activity From Intravenous (IV) and Subcutaneous (SC) Lutikizumab in Adult Participants With Active Ulcerative Colitis
Cambridge · Glasgow · London · OxfordCompleted 2027-09
A Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to Vedolizumab
London · North Finchley · Glasgow · Manchester · Oxford · Birmingham · StockportCompleted 2027-08
A Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to Vedolizumab
London · North Finchley · Glasgow · Manchester · Oxford · Birmingham · StockportCompleted 2027-08
A Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC)
Bath · Exeter · Basingstoke · London · Glasgow · Birmingham · HuddersfieldCompleted 2027-07
A Study of Guselkumab Administered Subcutaneously in Bio-naive Participants With Active Psoriatic Arthritis Axial Disease
Barnet · Bradford · Coventry · Leeds · Manchester · Newcastle · Stoke-on-TrentCompleted 2027-04-01
A Study of Guselkumab in Participants With Fistulizing, Perianal Crohn's Disease
Hull · London · Newcastle upon Tyne · SalfordCompleted 2027-03-25
Evaluation of Oral Tofacitinib in Children Aged 2 to 17 Years Old Suffering From Moderate to Severe Ulcerative Colitis
London · BirminghamCompleted 2027-03-17
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus
Bretton · London · Southampton · Northampton · Londonderry · Luton · PortsmouthCompleted 2027-03
A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn's Disease.
High Wycombe · Cambridge · London · North Finchley · Birmingham · Dudley · Prescot · StockportCompleted 2027-03
A Study to Assess the Efficacy and Safety of Afimkibart (Also Known as RO7790121) for Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis
Cambridge · Liverpool · LondonCompleted 2027-01-30
Rollover Study to Provide Continued Treatment for Participants With B-Cell Malignancies Previously Enrolled in Studies of Parsaclisib (INCB050465)
BirminghamCompleted 2026-11-05
A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (Also Known as RO7790121) in Participants With Moderately to Severely Active Ulcerative Colitis
Leicester · Llanrhystud · London · Peterborough · Stockport · WolverhamptonCompleted 2026-10-29
Filgotinib in Long-Term Extension Study of Adults With Ulcerative Colitis
Norwich · Bury · Cambridge · Derby · Edinburgh · Glasgow · High Wycombe · London · Nottingham · Oxford · Prescot · SouthamptonCompleted 2026-09-08
A Clinical Study of Tulisokibart (MK-7240) to Treat Rheumatoid Arthritis (RA) (MK-7240-014)
Harlow · Leeds · LondonCompleted 2026-09-07
A Clinical Study of Tulisokibart (MK-7240) to Treat Rheumatoid Arthritis (RA) (MK-7240-014)
Harlow · Leeds · LondonCompleted 2026-09-05
A Study to Evaluate Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderately to Severely Active Ulcerative Colitis (MK-7240-001)
Bristol · Cambridge · Exeter · Doncaster · Huddersfield · London · Southampton · West MidlandsCompleted 2026-08-12
Study Evaluating AZD7798 for Treatment in Crohn's Disease Patients With an Ileostomy
Birmingham · Cambridge · LondonCompleted 2026-08-10
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis
London · Kings Lynn · PortsmouthCompleted 2026-07-15
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis
London · Kings Lynn · PortsmouthCompleted 2026-07-15
Study to Measure Filgotinib in the Blood of Children and Teenagers With Arthritis Taking Filgotinib (SCALESIA)
LondonCompleted 2026-06-17
A Study of Mirikizumab (LY3074828) in Pediatric Participants With Moderately to Severely or Active Ulcerative Colitis
SheffieldCompleted 2026-05-01
ABTECT - Maintenance
Cambridge · London · Bury · Harrow · Yeovil · HuddersfieldCompleted 2026-04-28
Phase 2 Safety and Efficacy Study of Tulisokibart (MK-7240/PRA023) in Subjects With Systemic Sclerosis Associated With Interstitial Lung Disease (SSc-ILD) (MK-7240-007)
London · LeedsCompleted 2026-04-16
Study to Evaluate Tulisokibart for Hidradenitis Suppurativa (MK-7240-012)
Dudley · LondonCompleted 2026-04-02
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body)
Kirkcaldy · London · SalfordCompleted 2026-03-19
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body)
Kirkcaldy · London · SalfordCompleted 2026-03-19
A Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 3)
Bury · London · OxfordCompleted 2026-03-04
A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Study Participants With Active Psoriatic Arthritis
Barnet · Leeds · Luton · Manchester · Newcastle upon Tyne · Reading · SalfordCompleted 2026-02-06
A Study of Ustekinumab or Guselkumab in Pediatric Participants With Active Juvenile Psoriatic Arthritis
London · Manchester · Newcastle upon Tyne · Nottingham · Sheffield · Southampton · Staffordshire · Stoke-on-TrentCompleted 2026-01-12
A Study of Ustekinumab or Guselkumab in Pediatric Participants With Active Juvenile Psoriatic Arthritis
London · Manchester · Newcastle upon Tyne · Nottingham · Sheffield · Southampton · Staffordshire · Stoke-on-TrentCompleted 2026-01-12
A Phase 1b Trial to Evaluate the Safety of MB310 in Patients With Active, Mild-to-Moderate Ulcerative Colitis
Birmingham · Cambridge · LondonCompleted 2026-01-08
A Phase 1b Trial to Evaluate the Safety of MB310 in Patients With Active, Mild-to-Moderate Ulcerative Colitis
Birmingham · Cambridge · LondonCompleted 2026-01-08
A Study to Evaluate the Long-Term Effect of TEV-48574 in Moderate to Severe Ulcerative Colitis or Crohn's Disease
LondonCompleted 2026-01-05
A Study to Assess Efficacy and Safety of JNJ-77242113 Compared to Placebo and Ustekinumab in Participants With Moderate to Severe Plaque Psoriasis
Dudley · Harrow · Kings Lynn · London · Reading · Salford · Southampton · WakefieldCompleted 2025-11-17
A Study to Assess Efficacy and Safety of JNJ-77242113 Compared to Placebo and Ustekinumab in Participants With Moderate to Severe Plaque Psoriasis
Dudley · Harrow · Kings Lynn · London · Reading · Salford · Southampton · WakefieldCompleted 2025-11-17
A Study to Evaluate the Long-Term Efficacy, Safety, and Tolerability of Repeated Administration of Upadacitinib (ABT-494) in Participants With Crohn's Disease
Manchester · OxfordCompleted 2025-07-18
A Study of Vedolizumab in Children and Teenagers With Moderate to Severe Ulcerative Colitis (UC)
London · Birmingham · CardiffCompleted 2025-07-01
ABTECT-1 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -1
London · Bury · Harrow · Yeovil · Huddersfield · BelfastCompleted 2025-06-24
ABTECT-2 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -2
Cambridge · Exeter · LondonCompleted 2025-06-24
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease
Belfast · Birmingham · Cambridge · Glasgow · High Wycombe · London · Oxford · WolverhamptonCompleted 2025-05-23
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease
Belfast · Birmingham · Cambridge · Glasgow · High Wycombe · London · Oxford · WolverhamptonCompleted 2025-05-23
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease
Belfast · Birmingham · Cambridge · Glasgow · High Wycombe · London · Oxford · WolverhamptonCompleted 2025-05-23
Long Term Extension Study to Assess the Safety and Efficacy of Filgotinib in Adults With Rheumatoid Arthritis
Edinburgh · Harlow · North Shields · WarringtonCompleted 2025-05-16
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis
Belfast · Cambridge · Glasgow · High Wycombe · London · OxfordCompleted 2025-05-15
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis
Belfast · Cambridge · Glasgow · High Wycombe · London · OxfordCompleted 2025-05-15
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis
Belfast · Cambridge · Glasgow · High Wycombe · London · OxfordCompleted 2025-05-15
A Study of Ustekinumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis (UC)
Birmingham · Bristol · Cambridge · LondonCompleted 2025-05-08
A Study Evaluating the Efficacy and Safety of Oral Etrasimod in the Treatment of Adult Participants With Moderately to Severely Active Crohn's Disease
Liverpool · London · NorwichCompleted 2025-04-23
Long-term Safety and Efficacy Study of Adalimumab in Pediatric Subjects With Ulcerative Colitis
LondonCompleted 2025-04-08
Long-term Safety With Vedolizumab Intravenous (IV) in Pediatric Participants With Ulcerative Colitis (UC) or Crohn's Disease (CD)
LondonCompleted 2025-04-03
Long-Term Safety Study Of Tofacitinib In Patients With Juvenile Idiopathic Arthritis
BirminghamCompleted 2025-02-12
Adalimumab in JIA-associated Uveitis Stopping Trial
Bristol · Cambridge · Leicester · Liverpool · London · Manchester · Newcastle upon Tyne · Norwich · SheffieldCompleted 2025-01-23
A Study to Test Whether Spesolimab Helps People With a Skin Disease Called Netherton Syndrome
GlasgowCompleted 2025-01-13
An Extension Study of RPC1063 as Therapy for Moderate to Severe Ulcerative Colitis
LondonCompleted 2024-12-19
Experimental Medicine Studies of the Brain in Patients With Rheumatoid Arthritis REALISE
Cambridge · GlasgowCompleted 2024-11-29
A Long-term Extension Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease
Cambridge · London · CardiffCompleted 2024-11-28
A Study of Ustekinumab in Pediatric Participants With Moderately to Severely Active Crohn's Disease
Birmingham · Bristol · Cambridge · Edinburgh · LondonCompleted 2024-11-28
AZD7798 Safety, Tolerability, and Pharmacokinetics After a Single Ascending and Repeat Dose Administrations to Healthy Subjects, and Patients With Crohn's Disease
HarrowCompleted 2024-11-14
A Study to Test the Effect of TEV-48574 in Moderate to Severe Ulcerative Colitis or Crohn's Disease
LondonCompleted 2024-11-12
An Extension Study of Oral Ozanimod for Moderately to Severely Active Crohn's Disease
Southampton · London · Birmingham · Bristol · Cardiff · Chorley · Corbridge Road · Dundonald · Glasgow · Lancashire Blackpool · North Manchester Science Park · Shrewsbury · TorquayCompleted 2024-10-31
Severe Psoriatic Arthritis - Early intervEntion to Control Disease: the SPEED Trial
OxfordCompleted 2024-10-31
Severe Psoriatic Arthritis - Early intervEntion to Control Disease: the SPEED Trial
OxfordCompleted 2024-10-31
Severe Psoriatic Arthritis - Early intervEntion to Control Disease: the SPEED Trial
OxfordCompleted 2024-10-31
A Placebo-Controlled Study of Oral Ozanimod as Maintenance Therapy for Moderately to Severely Active Crohn's Disease
Southampton · London · Birmingham · Bristol · Cardiff · Chorley · Corbridge Road · Dundonald · Glasgow · Lancashire Blackpool · North Manchester Science Park · Shrewsbury · TorquayCompleted 2024-10-03
Induction Study #1 of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohn's Disease
Southampton · London · Birmingham · Bristol · Cardiff · Chorley · Corbridge Road · Dundonald · Glasgow · Lancashire Blackpool · North Manchester Science Park · Shrewsbury · TorquayCompleted 2024-10-01
A Study of JNJ-77242113 in Participants With Moderately to Severely Active Ulcerative Colitis
Bury · Cambridge · London · Oxford · Prescot · SouthamptonCompleted 2024-09-26
A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis
London · Reading · Salford · SouthamptonCompleted 2024-09-17
A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis
London · Reading · Salford · SouthamptonCompleted 2024-09-17
A Study Evaluating the Effect of Filgotinib in Participants With Active Axial Spondyloarthritis
Bath · NorwichCompleted 2024-09-04
A Study to Evaluate the Nipocalimab and Certolizumab Combination Therapy in Participants With Active Rheumatoid Arthritis
Edinburgh · Gillingham · LondonCompleted 2024-08-29
A Study of Mirikizumab (LY3074828) in Participants With Moderately to Severely Active Ulcerative Colitis
Bury · Waltham · LondonCompleted 2024-08-09
Lunsayil 1: A Study to Test Whether Spesolimab Helps People With a Skin Disease Called Hidradenitis Suppurativa
Gloucester · LondonCompleted 2024-08-01
A Study of JNJ-77242113 in Adolescent and Adult Participants With Moderate to Severe Plaque Psoriasis
Harrow · London · Reading · SalfordCompleted 2024-07-29
A Study to Assess Treat-to-Target and Dosing Flexibility of Oral Upadacitinib Tablets in Adult Participants With Moderate to Severe Atopic Dermatitis
Southampton · Glasgow · Leeds · EdinburghCompleted 2024-07-11
A Study to Test Whether BI 706321 Combined With Ustekinumab Helps People With Crohn's Disease
LiverpoolCompleted 2024-07-08
A Study to Test Whether BI 706321 Combined With Ustekinumab Helps People With Crohn's Disease
LiverpoolCompleted 2024-07-08
A Study of JNJ-77242113 for the Treatment of Participants With Plaque Psoriasis Involving Special Areas (Scalp, Genital, and/or Palms of the Hands and the Soles of the Feet)
Harrow · Salford · SouthamptonCompleted 2024-06-19
A Study of Long-term Effects of Vedolizumab Subcutaneous in Adults With Ulcerative Colitis and Crohn's Disease
Exeter · London · Norwich · Shrewsbury · Coventry · WolverhamptonCompleted 2024-06-12
Adalimumab vs. Conventional Immunosuppression for Uveitis Trial
Edgbaston · Bradford · Cambridge · Leicester · LondonCompleted 2024-04-02
A Study of Ixekizumab (LY2439821) in Children With Juvenile Idiopathic Arthritis Categories of Enthesitis-related Arthritis (Including Juvenile Onset Ankylosing Spondylitis) and Juvenile Psoriatic Arthritis
Bristol · Liverpool · Nottingham · Oxford · Stoke-on-Trent · SheffieldCompleted 2024-02-19
A Study of Subcutaneous Risankizumab Injection for Pediatric Participants With Moderate to Severe Plaque Psoriasis to Assess Change in Disease Symptoms
Exeter · Plymouth · London · Glasgow · CamberleyCompleted 2024-02-12
A Study of Subcutaneous Risankizumab Injection for Pediatric Participants With Moderate to Severe Plaque Psoriasis to Assess Change in Disease Symptoms
Exeter · Plymouth · London · Glasgow · CamberleyCompleted 2024-02-12
A Study to Evaluate the Safety and Efficacy of Upadacitinib in Participants With Giant Cell Arteritis
Bath · Exeter · Poole · London · Coventry · Liverpool · Portsmouth · Southend · TorquayCompleted 2024-02-06
A Study of the Safety of Oral Elsubrutinib Capsules and Oral Upadacitinib Tablets Given Alone or in Combination (ABBV-599) for Adult Participants With Moderately to Severely Active Systemic Lupus Erythematosus to Assess Change in Disease State
London · ManchesterCompleted 2024-01-03
Biologics in Refractory Vasculitis: A Trial of Biologic Therapy for Refractory Primary Non-ANCA Associated Vasculitis
Cambridge · Glasgow · London · MargateCompleted 2023-11-29
Biologics in Refractory Vasculitis: A Trial of Biologic Therapy for Refractory Primary Non-ANCA Associated Vasculitis
Cambridge · Glasgow · London · MargateCompleted 2023-11-29
GRAVITAS-309: Itacitinib and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease
Bristol · Cardiff · London · Nottingham · Sutton · TootingCompleted 2023-11-03
GRAVITAS-309: Itacitinib and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease
Bristol · Cardiff · London · Nottingham · Sutton · TootingCompleted 2023-11-03
GRAVITAS-309: Itacitinib and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease
Bristol · Cardiff · London · Nottingham · Sutton · TootingCompleted 2023-11-03
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease
Barnsley · Cambridge · LondonCompleted 2023-10-20
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease
Barnsley · Cambridge · LondonCompleted 2023-10-20
An Active and Placebo-Controlled Study of Brazikumab in Participants With Moderately to Severely Active Crohn's Disease
Coventry · West BromwichCompleted 2023-10-18
An Active and Placebo-Controlled Study of Brazikumab in Participants With Moderately to Severely Active Crohn's Disease
Coventry · West BromwichCompleted 2023-10-18
A Study Evaluating the Effect of Filgotinib Dose De-escalation in Participants With Ulcerative Colitis (UC) in Remission
Cambridge · Norwich · Prescot · SouthamptonCompleted 2023-10-09
A Study to Investigate the PK, Safety, and Tolerability Between AVT05, US and EU Simponi® in Healthy Adult Participants
LondonCompleted 2023-10-03
A Long-term Extension Study of JNJ-77242113 in Participants With Moderate-to-Severe Plaque Psoriasis
London · SouthamptonCompleted 2023-09-29
A Study of Guselkumab in Participants With Moderately to Severely Active Ulcerative Colitis
Glasgow · LondonCompleted 2023-09-19
Open-Label Extension Study of Upadacitinib in Adult Participants With Moderate to Severe Atopic Dermatitis
Kirkcaldy · London · Glasgow · WorthingCompleted 2023-09-11
A Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease
Cambridge · London · Manchester · Fulham · Cardiff · Birmingham · Doncaster · Edinburgh · HexhamCompleted 2023-08-23
A Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease
Cambridge · London · Manchester · Fulham · Cardiff · Birmingham · Doncaster · Edinburgh · HexhamCompleted 2023-08-23
Filgotinib in Long-Term Extension Study of Adults With Crohn's Disease
Norwich · Birmingham · Bury · Cambridge · Edinburgh · Exeter · Glasgow · High Wycombe · London · Oxford · Prescot · SouthamptonCompleted 2023-08-01
A Study of Baricitinib (LY3009104) in Participants From 2 Years to Less Than 18 Years Old With Active JIA-Associated Uveitis or Chronic Anterior Antinuclear Antibody-Positive Uveitis
Bristol · Cambridge · Liverpool · Newcastle upon Tyne · Southampton · London · SheffieldCompleted 2023-07-17
A HIV Vaccine Trial in Individuals Who Started Antiretrovirals During Primary or Chronic Infection (EHVA T02)
LondonCompleted 2023-07-12
GOLimumab and Methotrexate Versus Methotrexate in Very Early PsA
LeedsCompleted 2023-07
GOLimumab and Methotrexate Versus Methotrexate in Very Early PsA
LeedsCompleted 2023-07
Inflammatory Response In Schizophrenia
LondonCompleted 2023-06-15
A Study to Compare the Response to Treatment With Abatacept vs Adalimumab, on Background Methotrexate, in Adults With Early, Seropositive, and Shared Epitope-positive Rheumatoid Arthritis and an Inadequate Response to Methotrexate
Cannock · Hull · LondonCompleted 2023-06-14
A Study to Compare the Response to Treatment With Abatacept vs Adalimumab, on Background Methotrexate, in Adults With Early, Seropositive, and Shared Epitope-positive Rheumatoid Arthritis and an Inadequate Response to Methotrexate
Cannock · Hull · LondonCompleted 2023-06-14
A Study to Compare the Response to Treatment With Abatacept vs Adalimumab, on Background Methotrexate, in Adults With Early, Seropositive, and Shared Epitope-positive Rheumatoid Arthritis and an Inadequate Response to Methotrexate
Cannock · Hull · LondonCompleted 2023-06-14
A Phase 2 Safety and Efficacy Study of Tulisokibart (MK-7240/PRA023) in Subjects With Moderately to Severely Active Ulcerative Colitis (MK-7240-005)
Prescot · LondonCompleted 2023-06-06
The Anti-Freaze-F Study- "Anti-TNF for Treatment of Frozen Shoulder - a Feasibility Study"
Sutton Coldfield · Saint Leonards-on-Sea · Grantham · West BromwichCompleted 2023-05-09
BI 655130 Long-term Treatment in Patients With moderate-to Severe Ulcerative Colitis
Doncaster · London · PrescotCompleted 2023-05-03
Itacitinib in Advanced Hepatocellular Carcinoma
LondonCompleted 2023-04-07
Efficacy and Safety Study of ABX464 as Maintenance Therapy in Patients With Moderate to Severe Ulcerative Colitis
Bury · London · NottinghamCompleted 2023-02-23
A Study to Evaluate Efficacy, Safety, and Tolerability of EID of Natalizumab (BG00002) in Participants With RRMS Switching From Treatment With Natalizumab SID in Relation to Continued SID Treatment- Followed by Extension Study Comprising SC and IV Natalizumab Administration
London · Liverpool · Glasgow · Newcastle upon Tyne · Nottingham · Salford · Sheffield · SwanseaCompleted 2023-01-31
A Study to Test Long-term Treatment With Spesolimab in People With Palmoplantar Pustulosis (PPP) Who Took Part in Previous Studies With Spesolimab
Exeter · LondonCompleted 2023-01-16
A Multi-Site, Open-Label Extension Trial of Oral RPC1063 in Relapsing Multiple Sclerosis
East Sussex · Inverness · SheffieldCompleted 2023-01-05
Study to Assess the Efficacy, Safety, and Tolerability of Vixarelimab in Reducing Pruritus in Prurigo Nodularis
Edinburgh · Leytonstone · Liverpool · SouthamptonCompleted 2022-12-28
A Study of JNJ-77242113 in Participants With Moderate-to-severe Plaque Psoriasis
Cottingham · Dudley · London · Southampton · WakefieldCompleted 2022-12-15
Filgotinib in the Induction and Maintenance of Remission in Adults With Moderately to Severely Active Crohn's Disease
Norwich · Birmingham · Bury · Cambridge · Derby · Edinburgh · Exeter · Glasgow · High Wycombe · Hull · London · Oxford · Prescot · SouthamptonCompleted 2022-11-11
A Multicenter, Randomized, Double-Blind, Placebo Controlled Induction Study to Evaluate the Efficacy and Safety of Risankizumab in Participants With Moderately to Severely Active Ulcerative Colitis
Exeter · Southampton · London · Barnsley · Cambridge · Edinburgh · Liverpool · Newcastle upon Tyne · TootingCompleted 2022-11-09
Biologics for Rheumatoid Arthritis Pain (BIORA-PAIN)
LondonCompleted 2022-10-26
Biologics for Rheumatoid Arthritis Pain (BIORA-PAIN)
LondonCompleted 2022-10-26
A Study to Evaluate the Efficacy and Safety of PF-06480605 in Adults With Moderate to Severe Ulcerative Colitis
Sutton Coldfield · Northwood · Corby · High Wycombe · Nottingham · OrpingtonCompleted 2022-10-25
Efficacy and Safety of Brodalumab Compared With Guselkumab in the Treatment of Plaque Psoriasis After Inadequate Response to Ustekinumab
Bath · Dudley · Leeds · LondonCompleted 2022-09-08
Efficacy and Safety of Brodalumab Compared With Guselkumab in the Treatment of Plaque Psoriasis After Inadequate Response to Ustekinumab
Bath · Dudley · Leeds · LondonCompleted 2022-09-08
Efficacy and Safety of Brodalumab Compared With Guselkumab in the Treatment of Plaque Psoriasis After Inadequate Response to Ustekinumab
Bath · Dudley · Leeds · LondonCompleted 2022-09-08
A Study to Evaluate Efficacy and Safety of Ustekinumab Re-induction Therapy in Participants With Moderately to Severely Active Crohn's Disease
Bury · Cheltenham · Exeter · London · SouthamptonCompleted 2022-08-19
A Study of LY3471851 in Adult Participants With Moderately to Severely Active Ulcerative Colitis (UC)
Derby · Leytonstone · London · YorkCompleted 2022-08-09
Tofacitinib in Depression (TIDE)
OxfordCompleted 2022-05-23
Etrasimod Versus Placebo for the Treatment of Moderately to Severely Active Ulcerative Colitis
London · Norwich · Yeovil · Belfast · Hemel HempsteadCompleted 2022-02-08
A Long-term Study to Evaluate Safety and Maintenance of Treatment Effect of LY3074828 in Participants With Moderate-to-Severe Plaque Psoriasis (OASIS-3)
SalfordCompleted 2022-02-07
Vedolizumab in the Prophylaxis of Intestinal Acute Graft Versus Host Disease (aGVHD) in Participants Undergoing Allogeneic Hematopoietic Stem Cell (Allo-HSCT) Transplantation
Liverpool · London · Sheffield · CardiffCompleted 2022-02-07
A Study to Investigate the Safety and Efficacy of Elsubrutinib and Upadacitinib Given Alone or in Combination in Participants With Moderately to Severely Active Systemic Lupus Erythematosus (SLE)
London · Cambridge · ManchesterCompleted 2022-01-19
A Study of the Safety and Efficacy of Risankizumab in Adult Participants With Plaque Psoriasis Who Have Had a Suboptimal Response to Secukinumab or Ixekizumab
Kirkcaldy · Dudley · Leeds · Newcastle upon Tyne · SalfordCompleted 2022-01-17
A Study of the Safety and Efficacy of Risankizumab in Adult Participants With Plaque Psoriasis Who Have Had a Suboptimal Response to Secukinumab or Ixekizumab
Kirkcaldy · Dudley · Leeds · Newcastle upon Tyne · SalfordCompleted 2022-01-17
Predicting Response to Vedolizumab in Pediatric Inflammatory Bowel Diseases
GlasgowCompleted 2022-01
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of UTTR1147A Compared With Placebo and With Vedolizumab in Participants With Moderate to Severe Ulcerative Colitis (UC)
LondonCompleted 2021-12-15
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of UTTR1147A Compared With Placebo and With Vedolizumab in Participants With Moderate to Severe Ulcerative Colitis (UC)
LondonCompleted 2021-12-15
A Study to Evaluate the Safety and Efficacy of Upadacitinib (ABT-494) for Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis (UC)
Exeter · Basingstoke · London · Glasgow · Bath · Birmingham · Huddersfield · TootingCompleted 2021-12-13
Etrasimod Versus Placebo as Induction Therapy in Moderately to Severely Active Ulcerative Colitis
London · Norwich · YeovilCompleted 2021-12-07
A Study to Evaluate the Effect of Ustekinumab on Cytochrome P450 Enzyme Activities Following Induction and Maintenance Dosing in Participants With Active Crohn's Disease or Ulcerative Colitis
Greater Manchester · Liverpool · LondonCompleted 2021-11-22
Effect of Secukinumab on Radiographic Progression in Ankylosing Spondylitis as Compared to GP2017 (Adalimumab Biosimilar)
Christchurch · London · Portsmouth · Leytonstone · Stoke-on-Trent · Bath · Bristol · Leicester · Liverpool · Norwich · Torquay · WolverhamptonCompleted 2021-11-12
Effect of Secukinumab on Radiographic Progression in Ankylosing Spondylitis as Compared to GP2017 (Adalimumab Biosimilar)
Christchurch · London · Portsmouth · Leytonstone · Stoke-on-Trent · Bath · Bristol · Leicester · Liverpool · Norwich · Torquay · WolverhamptonCompleted 2021-11-12
A Maintenance Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis
Romford · Bury · Great Maze Pond · London · Swansea · LeedsCompleted 2021-11-03
Efficacy and Safety of GSK3196165 Versus Placebo and Tofacitinib in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Conventional Synthetic (cs)/Biologic (b) Disease Modifying Anti-rheumatic Drugs (DMARDs)
Romford · Northwood · KenilworthCompleted 2021-10-29
A Study of the Efficacy and Safety of Upadacitinib in Participants With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Conventional and/or Biologic Therapies
Belfast · Warrington · Bath · Birmingham · Dudley · London · Newcastle upon Tyne · Stockport · Taunton · Tooting · WolverhamptonCompleted 2021-10-15
Efficacy and Safety of GSK3196165 Versus Placebo and Tofacitinib in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate
Romford · Northwood · KenilworthCompleted 2021-09-15
Efficacy and Safety of GSK3196165 Versus Placebo and Tofacitinib in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate
Romford · Northwood · KenilworthCompleted 2021-09-15
A Study to Evaluate Efficacy and Safety of Upadacitinib in Adults With Axial Spondyloarthritis
Preston · Norwich · Bury St Edmunds · Armthorpe RoadCompleted 2021-09-02
A Study to Test the Efficacy and Safety of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis
Leeds · WolverhamptonCompleted 2021-08-17
A Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Biologic Therapy
Belfast · Warrington · London · Bath · Birmingham · Dudley · Harrow · Newcastle upon Tyne · Stockport · Taunton · Tooting · WolverhamptonCompleted 2021-08-11
An Open-label Extension Study Evaluating the Safety and Efficacy of Upadacitinib (ABT-494) in Adults With Rheumatoid Arthritis
Warrington · London · Bury St Edmunds · LeedsCompleted 2021-07-29
Evaluation of the Potential CYP1A2-mediated Drug Drug Interaction Safety, and Tolerability of ABX464
Merthyr TydfilCompleted 2021-05-18
Safety, Tolerability, Efficacy and Dose-response of GSK2831781 in Ulcerative Colitis
Cambridge · Headington · LondonCompleted 2021-05-17
Dose-Ranging Phase 2b Study of ABX464 in Moderate to Severe Ulcerative Colitis
Bury · London · NottinghamCompleted 2021-04-01
A Study to Evaluate Upadacitinib in Adolescents and Adults With Moderate to Severe Atopic Dermatitis (Measure Up 2)
Southampton · Middlesex · London · Newcastle upon Tyne · PlymouthCompleted 2021-03-11
ABX464 in Treating Inflammation and Preventing Acute Respiratory Failure in Patients With COVID-19
LondonCompleted 2021-03-05
A Study of Guselkumab for the Treatment of Palmoplantar-non-Pustular Psoriasis
Dudley · Leeds · London · Newcastle upon Tyne · SalfordCompleted 2021-03-02
A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis
London · Oxford · Dundee · Glasgow · LeedsCompleted 2021-02-16
An Induction Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 1)
Romford · Bury · Winchester · Great Maze Pond · Dundee · London · Swansea · Leeds · GlasgowCompleted 2021-01-21
Study to Evaluate the Efficacy and Safety of Filgotinib in the Treatment of Perianal Fistulizing Crohn's Disease
ExeterCompleted 2021-01-20
A Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Moderately to Severely Active Ulcerative Colitis
Basingstoke · Glasgow · Huddersfield · London · WhitechapelCompleted 2021-01-14
Evaluation of Upadacitinib in Adolescent and Adult Patients With Moderate to Severe Atopic Dermatitis (Eczema)
Isleworth · London · SalfordCompleted 2021-01-06
Study to Evaluate the Efficacy and Safety of Filgotinib in Adults With Active Noninfectious Uveitis
Liverpool · London · Manchester · OxfordCompleted 2020-12-29
Study to Evaluate the Efficacy and Safety of Filgotinib in Adults With Active Noninfectious Uveitis
Liverpool · London · Manchester · OxfordCompleted 2020-12-29
Safety and Efficacy of Adalimumab Versus Ustekinumab for One Year
Bath · Bury · Kingston upon Thames · London · Southampton · TauntonCompleted 2020-12-15
Safety and Efficacy of Adalimumab Versus Ustekinumab for One Year
Bath · Bury · Kingston upon Thames · London · Southampton · TauntonCompleted 2020-12-15
Safety and Efficacy Study of JNJ-64304500 in Participants With Moderately to Severely Active Crohn's Disease
Cambridge · Nottingham · Sheffield · Sutton in AshfieldCompleted 2020-12-10
Safety and Efficacy Study of JNJ-64304500 in Participants With Moderately to Severely Active Crohn's Disease
Cambridge · Nottingham · Sheffield · Sutton in AshfieldCompleted 2020-12-10
A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Moderately to Severely Active Crohn's Disease Who Failed Prior Biologic Treatment
Glasgow · Chertsey · Barnsley · Birmingham · Cambridge · Edinburgh · Hull · London · Newcastle upon Tyne · Oxford · SalfordCompleted 2020-11-30
Study to Evaluate the Testicular Safety of Filgotinib in Adult Males With Moderately to Severely Active Inflammatory Bowel Disease
CambridgeCompleted 2020-11-20
A Study of Guselkumab in Participants With Active Psoriatic Arthritis and an Inadequate Response to Anti-Tumor Necrosis Factor Alpha (Anti-TNF Alpha) Therapy
Bath · Cambridge · Cannock · Leeds · London · Newcastle · Peterborough · Stoke-on-Trent · TorquayCompleted 2020-11-11
A Study of the Efficacy and Safety of Risankizumab in Participants With Moderately to Severely Active Crohn's Disease
Exeter · London · Chertsey · Cambridge · Edinburgh · Huddersfield · Hull · Leeds · Newcastle upon Tyne · Oxford · SalfordCompleted 2020-11-09
Repurposing Anti-TNF for Treating Dupuytren's Disease
Edinburgh · OxfordCompleted 2020-11
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy
London · Glasgow · Stafford · Manchester · Metropolitan Borough of Wirral · Portsmouth · TorquayCompleted 2020-10-08
A Study in Rheumatoid Arthritis Patients Who Have Completed a Preceding Study With ABBV-105 Given Alone or in Combination With Upadacitinib
OxfordCompleted 2020-09-09
A Study to Compare Safety and Efficacy of Upadacitinib to Dupilumab in Adult Participants With Moderate to Severe Atopic Dermatitis
Brighton · Kirkcaldy · Glasgow · London · CardiffCompleted 2020-08-27
A Study to Compare Safety and Efficacy of Upadacitinib to Dupilumab in Adult Participants With Moderate to Severe Atopic Dermatitis
Brighton · Kirkcaldy · Glasgow · London · CardiffCompleted 2020-08-27
Long-Term Study Of CP-690,550 In Subjects With Ulcerative Colitis
Bristol · Cambridge · Harrow · Norwich · LondonCompleted 2020-08-06
A Study to Test How Effective and Safe Different Doses of BI 655130 Are in Patients With a Moderate to Severe Form of the Skin Disease Palmoplantar Pustulosis
Exeter · LondonCompleted 2020-08-06
Safety Study Of Tofacitinib Versus Tumor Necrosis Factor (TNF) Inhibitor In Subjects With Rheumatoid Arthritis
Poole · Goodmayes · Cannock · Liverpool · Newcastle upon Tyne · North Shields · WolverhamptonCompleted 2020-07-22
Safety Study Of Tofacitinib Versus Tumor Necrosis Factor (TNF) Inhibitor In Subjects With Rheumatoid Arthritis
Poole · Goodmayes · Cannock · Liverpool · Newcastle upon Tyne · North Shields · WolverhamptonCompleted 2020-07-22
Study to Evaluate the Efficacy and Safety of Filgotinib in the Treatment of Small Bowel Crohn's Disease (SBCD)
Glasgow · Exeter · London · OxfordCompleted 2020-07-20
Risankizumab Versus Secukinumab for Participants With Moderate to Severe Plaque Psoriasis
London · SalfordCompleted 2020-07-08
Risankizumab Versus Secukinumab for Participants With Moderate to Severe Plaque Psoriasis
London · SalfordCompleted 2020-07-08
A Study Comparing the Efficacy and Safety of Etrolizumab to Infliximab in Participants With Moderate to Severe Ulcerative Colitis Who Are Naïve to Tumor Necrosis Factor (TNF) Inhibitors
Bournemouth · Cambridge · Coventry · Exeter · Leeds · London · Manchester · Newcastle upon Tyne · Nottingham · SouthamptonCompleted 2020-06-23
A Study Comparing the Efficacy and Safety of Etrolizumab to Infliximab in Participants With Moderate to Severe Ulcerative Colitis Who Are Naïve to Tumor Necrosis Factor (TNF) Inhibitors
Bournemouth · Cambridge · Coventry · Exeter · Leeds · London · Manchester · Newcastle upon Tyne · Nottingham · SouthamptonCompleted 2020-06-23
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies)
London · Manchester · Metropolitan Borough of Wirral · TorquayCompleted 2020-06-22
A Study to Evaluate the Efficacy and Safety of Vedolizumab in the Treatment of Chronic Pouchitis
Harrow · London · OxfordCompleted 2020-06-11
A Study to Evaluate the Efficacy and Safety of Vedolizumab in the Treatment of Chronic Pouchitis
Harrow · London · OxfordCompleted 2020-06-11
BI655130 (SPESOLIMAB) Induction Treatment in Patients With Moderate-to-severe Ulcerative Colitis
Barnsley · Doncaster · London · PrescotCompleted 2020-05-18
A Study of Ruxolitinib vs Best Available Therapy (BAT) in Patients With Steroid-refractory Chronic Graft vs. Host Disease (GvHD) After Bone Marrow Transplantation (REACH3)
Glasgow · London · ManchesterCompleted 2020-05-08
A Study of Ruxolitinib vs Best Available Therapy (BAT) in Patients With Steroid-refractory Chronic Graft vs. Host Disease (GvHD) After Bone Marrow Transplantation (REACH3)
Glasgow · London · ManchesterCompleted 2020-05-08
A Study of Ruxolitinib vs Best Available Therapy (BAT) in Patients With Steroid-refractory Chronic Graft vs. Host Disease (GvHD) After Bone Marrow Transplantation (REACH3)
Glasgow · London · ManchesterCompleted 2020-05-08
A Study of Ruxolitinib vs Best Available Therapy (BAT) in Patients With Steroid-refractory Chronic Graft vs. Host Disease (GvHD) After Bone Marrow Transplantation (REACH3)
Glasgow · London · ManchesterCompleted 2020-05-08
Study of Treat to Target Versus Routine Care Maintenance Strategies in Crohn's Disease Patients Treated With Ustekinumab
Belfast · Darlington · Dundee · Glasgow · London · Prescot · Salford · Southampton · TauntonCompleted 2020-04-30
Efficacy and Safety of BMS-986165 Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA)
Bradford · HarlowCompleted 2020-04-27
Efficacy and Safety of BMS-986165 Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA)
Bradford · HarlowCompleted 2020-04-27
Study to Evaluate the Efficacy and Safety of Filgotinib in the Induction and Maintenance of Remission in Adults With Moderately to Severely Active Ulcerative Colitis
Bury · Cambridge · Derby · Edinburgh · Glasgow · High Wycombe · London · Norwich · Nottingham · Oxford · Prescot · SouthamptonCompleted 2020-03-31
Vedolizumab IV in Pediatric Participants With Ulcerative Colitis (UC) or Crohn's Disease (CD)
Birmingham · Cambridge · London · Manchester · Nottingham · Oxford · Sheffield · GlasgowCompleted 2020-03-31
Safety and Efficacy Trial of RPC1063 for Moderate to Severe Ulcerative Colitis
Coventry · Exeter · Gloucester · London · ShrewsburyCompleted 2020-03-27
A Study in Patients With Mild or Moderate Ulcerative Colitis Who Take a TNF Inhibitor. The Study Investigates Whether Bowel Inflammation Improves When Patients Take BI 655130 in Addition to Their Current Therapy
Leeds · London · PrescotCompleted 2020-03-26
A Study to Investigate the Safety and Efficacy of ABBV-105 Alone or in Combination With Upadacitinib (ABBV-599 Combination) in Participants With Active Rheumatoid Arthritis
Newcastle upon Tyne · Oxford · WarringtonCompleted 2020-03-26
A Study to Assess if Mirikizumab is Effective and Safe Compared to Secukinumab and Placebo in Moderate to Severe Plaque Psoriasis (OASIS-2)
SalfordCompleted 2020-03-05
A Study to Assess if Mirikizumab is Effective and Safe Compared to Secukinumab and Placebo in Moderate to Severe Plaque Psoriasis (OASIS-2)
SalfordCompleted 2020-03-05
Investigation of the Faecal Loss of Vedolizumab and Its Role in Influencing Serum Drug Levels, Outcomes and Response in Ulcerative Colitis
LondonCompleted 2020-03
Safety and Efficacy of Itacitinib in Combination With Corticosteroids for Treatment of Graft-Versus-Host Disease in Pediatric Subjects
Birmingham · Bristol · Leeds · London · Manchester · Surrey QuaysCompleted 2020-02-17
A Study of Tofacitinib in Patients With Ulcerative Colitis in Stable Remission
BristolCompleted 2020-02-14
Efficacy and Safety of Adalimumab in Pediatric Subjects With Moderate to Severe Ulcerative Colitis
London · Glasgow · ManchesterCompleted 2020-02-07
Study to Evaluate Efficacy and Safety of Two Drug Regimens in Subjects With Moderate to Severe Crohn's Disease
London · Norwich · Hull · Southampton · WolverhamptonCompleted 2020-01-30
Efficacy of Secukinumab Compared to Adalimumab in Patients With Psoriatic Arthritis
Torquay · Leytonstone · Salford · Cannock · Stoke-on-Trent · Edinburgh · Glasgow · Hull · London · Newcastle upon Tyne · Plymouth · Solihull · Wigan · WolverhamptonCompleted 2019-12-30
Efficacy of Secukinumab Compared to Adalimumab in Patients With Psoriatic Arthritis
Torquay · Leytonstone · Salford · Cannock · Stoke-on-Trent · Edinburgh · Glasgow · Hull · London · Newcastle upon Tyne · Plymouth · Solihull · Wigan · WolverhamptonCompleted 2019-12-30
Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of GSK2831781 After an Intravenous (IV) Dose in Healthy Japanese and Caucasian Subjects, and a Subcutaneous (SC) Dose in Healthy Caucasian Subjects
LondonCompleted 2019-12-10
Study of the Golimumab Exposure-Response Relationship Using Serum Trough Levels
LondonCompleted 2019-09-30
A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Participants With Psoriatic Arthritis Who Have an Inadequate Response to at Least One Non-Biologic Disease Modifying Anti-Rheumatic Drug (DMARD)
London · Christchurch · Coventry · Glasgow · LutonCompleted 2019-09-26
A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Participants With Psoriatic Arthritis Who Have an Inadequate Response to at Least One Non-Biologic Disease Modifying Anti-Rheumatic Drug (DMARD)
London · Christchurch · Coventry · Glasgow · LutonCompleted 2019-09-26
A Study of Subjects With Psoriatic Arthritis to Investigate the Effectiveness of Adalimumab Introduction Compared With Methotrexate Dose Escalation (CONTROL)
Bath · Edinburgh · Londonderry · Manchester · PrestonCompleted 2019-09-23
A Study of Subjects With Psoriatic Arthritis to Investigate the Effectiveness of Adalimumab Introduction Compared With Methotrexate Dose Escalation (CONTROL)
Bath · Edinburgh · Londonderry · Manchester · PrestonCompleted 2019-09-23
Study to Evaluate the Safety and Efficacy of Two Adalimumab Dosing Regimens in Subjects With Moderate to Severe Ulcerative Colitis
Winchester · Norwich · Edinburgh · Harrow · Hull · Oxford · Southampton · WolverhamptonCompleted 2019-09-05
This Study Tests How BI 655130 Works in Patients With Active Ulcerative Colitis. The Study Also Tests How Well BI 655130 is Tolerated and Whether it Helps the Patients
CambridgeCompleted 2019-08-05
Evaluation of the Efficacy and Safety of Two Dosing Regimens of Olokizumab (OKZ), Compared to Placebo and Adalimumab, in Subjects With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate But Have Active Disease
Torquay · London · Basingstoke · Maidstone · Metropolitan Borough of WirralCompleted 2019-08-02
Evaluation of the Efficacy and Safety of Two Dosing Regimens of Olokizumab (OKZ), Compared to Placebo and Adalimumab, in Subjects With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate But Have Active Disease
Torquay · London · Basingstoke · Maidstone · Metropolitan Borough of WirralCompleted 2019-08-02
A Study Comparing Upadacitinib (ABT-494) to Placebo in Participants With Active Psoriatic Arthritis Who Have a History of Inadequate Response to at Least One Biologic Disease Modifying Anti-Rheumatic Drug
Bath · London · Glasgow · Luton · PooleCompleted 2019-07-23
An HIV Vaccine Trial in Individuals Who Started ART During Primary or Chronic Infection
LondonCompleted 2019-07-11
A Long Term Extension Trial of BI 655066/ABBV-066 (Risankizumab), in Patients With Moderately to Severely Active Crohn's Disease
London · Cambridge · Leeds · Newcastle upon Tyne · OxfordCompleted 2019-06-19
Study of LY3074828 in Healthy Participants
LeedsCompleted 2019-06-18
A Phase 3 Study to Compare Upadacitinib to Abatacept in Subjects With Rheumatoid Arthritis on Stable Dose of Conventional Synthetic Disease- Modifying Antirheumatic Drugs (csDMARDs) Who Have an Inadequate Response or Intolerance to Biologic DMARDs
London · Dundee · Londonderry · Preston · TruroCompleted 2019-06-13
A Phase 3 Study to Compare Upadacitinib to Abatacept in Subjects With Rheumatoid Arthritis on Stable Dose of Conventional Synthetic Disease- Modifying Antirheumatic Drugs (csDMARDs) Who Have an Inadequate Response or Intolerance to Biologic DMARDs
London · Dundee · Londonderry · Preston · TruroCompleted 2019-06-13
Open-Label Extension Study Of Tofacitinib In Psoriatic Arthritis
Goodmayes · Romford · Dudley · Bradford · Upton · Bath · YorkCompleted 2019-05-20
Open-Label Extension Study Of Tofacitinib In Psoriatic Arthritis
Goodmayes · Romford · Dudley · Bradford · Upton · Bath · YorkCompleted 2019-05-20
A Phase 3 Study of NI-071 in Participants With Rheumatoid Arthritis (RADIANCE)
Bury St Edmunds · Gillingham · Leicester · TruroCompleted 2019-05-20
Efficacy Study Of Tofacitinib In Pediatric JIA Population
Southampton · BirminghamCompleted 2019-05-16
Safety and Efficacy of Adalimumab (Humira) for Hidradenitis Suppurativa (HS) Peri-Surgically
LondonCompleted 2019-05-16
Efficacy and Safety of Vedolizumab Subcutaneous (SC) as Maintenance Therapy in Crohn's Disease (CD)
Exeter · London · Shrewsbury · CoventryCompleted 2019-05-06
GRAVITAS-301: A Study of Itacitinib or Placebo in Combination With Corticosteroids for Treatment of Acute Graft-Versus-Host Disease
Cambridge · Cardiff · London · NottinghamCompleted 2019-05-02
GRAVITAS-301: A Study of Itacitinib or Placebo in Combination With Corticosteroids for Treatment of Acute Graft-Versus-Host Disease
Cambridge · Cardiff · London · NottinghamCompleted 2019-05-02
GRAVITAS-301: A Study of Itacitinib or Placebo in Combination With Corticosteroids for Treatment of Acute Graft-Versus-Host Disease
Cambridge · Cardiff · London · NottinghamCompleted 2019-05-02
BI 695501 Versus Humira in Patients With Active Crohn's Disease: a Trial Comparing Efficacy, Endoscopic Improvement, Safety, and Immunogenicity
Bournemouth · WalsallCompleted 2019-04-30
BI 695501 Versus Humira in Patients With Active Crohn's Disease: a Trial Comparing Efficacy, Endoscopic Improvement, Safety, and Immunogenicity
Bournemouth · WalsallCompleted 2019-04-30
Study to Evaluate Maintenance of Sustained Remission of axSpA With CZP Compared to Placebo
Leeds · NorwichCompleted 2019-02
A Study Evaluating the Safety and Efficacy of Upadacitinib in Adults With Active Ankylosing Spondylitis
Warrington · London · Norwich · Bath · GlasgowCompleted 2019-01-21
Study to Assess Safety and Efficacy of Filgotinib, Lanraplenib and Tirabrutinib in Adults With Active Sjogren's Syndrome
Doncaster · Edinburgh · Harlow · Swindon · WarringtonCompleted 2019-01-10
A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to Placebo and an Active Comparator in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis
Cardiff · Dundee · Edgbaston · Liverpool · Manchester · SalfordCompleted 2019-01-08
A Study of Mirikizumab (LY3074828) in Participants With Active Crohn's Disease
GlasgowCompleted 2018-12-11
Methotrexate Withdrawal Study of Tofacitinib Modified Release Formulation in Subjects With Rheumatoid Arthritis
Chester · Ellesmere Port · Basingstoke · Metropolitan Borough of Wirral · Dudley · ManchesterCompleted 2018-11-19
Methotrexate Withdrawal Study of Tofacitinib Modified Release Formulation in Subjects With Rheumatoid Arthritis
Chester · Ellesmere Port · Basingstoke · Metropolitan Borough of Wirral · Dudley · ManchesterCompleted 2018-11-19
A Study of Ixekizumab (LY2439821) Versus Adalimumab in Participants With Psoriatic Arthritis
Cambridge · Truro · Southampton · Wythenshawe · Wishaw · Edinburgh · London · North Shields · Dudley · Wolverhampton · Bradford · SwindonCompleted 2018-11-15
Extension Study of APD334-003 in Patients With Moderately to Severely Active Ulcerative Colitis
London · Torquay · WolverhamptonCompleted 2018-11-01
Filgotinib Alone and in Combination With Methotrexate (MTX) in Adults With Moderately to Severely Active Rheumatoid Arthritis Who Are Naive to MTX Therapy
Edinburgh · Newcastle upon TyneCompleted 2018-10-05
Filgotinib Alone and in Combination With Methotrexate (MTX) in Adults With Moderately to Severely Active Rheumatoid Arthritis Who Are Naive to MTX Therapy
Edinburgh · Newcastle upon TyneCompleted 2018-10-05
An Efficacy and Safety Study of Vedolizumab Intravenous (IV) Compared to Adalimumab Subcutaneous (SC) in Participants With Ulcerative Colitis
Plymouth · Salford · Norwich · Glasgow · Coventry · WolverhamptonCompleted 2018-09-26
An Efficacy and Safety Study of Vedolizumab Intravenous (IV) Compared to Adalimumab Subcutaneous (SC) in Participants With Ulcerative Colitis
Plymouth · Salford · Norwich · Glasgow · Coventry · WolverhamptonCompleted 2018-09-26
Vedolizumab IV 300 mg in the Treatment of Fistulizing Crohn's Disease
Nottingham · OxfordCompleted 2018-09-04
A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis
Birmingham · Cambridge · Coventry · Doncaster · Edinburgh · Liverpool · London · Salford · Southampton · Sutton in AshfieldCompleted 2018-08-10
Filgotinib in Combination With Methotrexate in Adults With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate
Poole · Doncaster · Edinburgh · Newcastle upon Tyne · WarringtonCompleted 2018-07-04
Filgotinib in Combination With Methotrexate in Adults With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate
Poole · Doncaster · Edinburgh · Newcastle upon Tyne · WarringtonCompleted 2018-07-04
Filgotinib in Combination With Methotrexate in Adults With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate
Poole · Doncaster · Edinburgh · Newcastle upon Tyne · WarringtonCompleted 2018-07-04
Efficacy and Safety of Vedolizumab Subcutaneously (SC) as Maintenance Therapy in Ulcerative Colitis
Exeter · LondonCompleted 2018-05-30
MSB11022 in Moderate to Severe Rheumatoid Arthritis
Glasgow · LondonCompleted 2018-05-28
MSB11022 in Moderate to Severe Rheumatoid Arthritis
Glasgow · LondonCompleted 2018-05-28
A Phase 4 Trial Assessing the ImPact of Residual Inflammation Detected Via Imaging TEchniques, Drug Levels and Patient Characteristics on the Outcome of Dose TaperIng of Adalimumab in Clinical Remission Rheumatoid ArThritis (RA) Subjects
London · Chelmsford · Edinburgh · Leeds · Liverpool · PortsmouthCompleted 2018-05-03
A Study of Mirikizumab (LY3074828) Injection in Healthy Participants
LeedsCompleted 2018-04-03
Filgotinib Versus Placebo in Adults With Active Rheumatoid Arthritis (RA) Who Have an Inadequate Response to Biologic Disease-modifying Anti-rheumatic Drug(s) (DMARDs) Treatment
Doncaster · Edinburgh · Goodmayes · Harlow · Newcastle upon TyneCompleted 2018-03-20
A Study to Compare Upadacitinib (ABT-494) Monotherapy to Methotrexate (MTX) Monotherapy in Adults With Rheumatoid Arthritis (RA) Who Have Not Previously Taken Methotrexate
Leicester · London · Edinburgh · Leeds · Portsmouth · SouthamptonCompleted 2018-03-15
A Study to Compare Upadacitinib (ABT-494) Monotherapy to Methotrexate (MTX) Monotherapy in Adults With Rheumatoid Arthritis (RA) Who Have Not Previously Taken Methotrexate
Leicester · London · Edinburgh · Leeds · Portsmouth · SouthamptonCompleted 2018-03-15
A First in Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of a Intravenous (IV) Dose of GSK2831781 in Healthy Volunteers and Patients With Plaque Psoriasis
LondonCompleted 2018-03-07
A Study to Assess the Amount of LY3074828 That Gets Into the Body When Given With LY9999QS, in Healthy Participants
LeedsCompleted 2018-02-23
Safety and Efficacy of Etrasimod (APD334) in Patients With Ulcerative Colitis
London · Torquay · WolverhamptonCompleted 2018-02-14
A Study of Mirikizumab (LY3074828) in Participants With Moderate to Severe Ulcerative Colitis
Oxford · WinchesterCompleted 2017-12-19
Targeted Ultrasound in Rheumatoid Arthritis
LeedsCompleted 2017-12
Safety and Efficacy of Intravenous Natalizumab in Acute Ischemic Stroke
London · Harrow · Stoke-on-TrentCompleted 2017-11-20
A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate
London · Portsmouth · WarringtonCompleted 2017-10-27
A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate
London · Portsmouth · WarringtonCompleted 2017-10-27
A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate
London · Portsmouth · WarringtonCompleted 2017-10-27
Efficacy and Safety of BI 655066/ABBV-066 (Risankizumab) in Patients With Severe Persistent Asthma
Belfast · Bradford · Leicester · Manchester · WishawCompleted 2017-10-13
An Efficacy and Safety Study of Ustekinumab in Participants With Active Nonradiographic Axial Spondyloarthritis
Bath · Leeds · Leytonstone · London · Norwich · Staffordshire · TorquayCompleted 2017-09-26
Thermography in Assessing Treatment Response to Golimumab in Psoriatic Arthritis
LondonCompleted 2017-09-19
A Study to Evaluate the Efficacy and Safety of Ustekinumab in the Treatment of Anti-TNF(Alpha) Refractory Participants With Active Radiographic Axial Spondyloarthritis
Bath · Leytonstone · London · Peterborough · Stoke-on-Trent · UptonCompleted 2017-08-31
A Study to Evaluate the Efficacy and Safety of Ustekinumab in the Treatment of Anti-TNF(Alpha) Refractory Participants With Active Radiographic Axial Spondyloarthritis
Bath · Leytonstone · London · Peterborough · Stoke-on-Trent · UptonCompleted 2017-08-31
A Study Comparing Upadacitinib (ABT-494) to Placebo in Adults With Rheumatoid Arthritis on a Stable Dose of Conventional Synthetic Disease-Modifying Antirheumatic Drugs (csDMARDs) Who Have an Inadequate Response to csDMARDs Alone
Leicester · London · Edinburgh · Southampton · WarringtonCompleted 2017-04-21
A Study to Compare Upadacitinib (ABT-494) to Placebo in Adults With Rheumatoid Arthritis on Stable Dose of Conventional Synthetic Disease-Modifying Antirheumatic Drugs (csDMARDs) With an Inadequate Response or Intolerance to Biologic DMARDs
London · Chelmsford · Edinburgh · Ipswich · Metropolitan Borough of Wirral · PortsmouthCompleted 2017-04-03
Multiple Dose Study of UCB4940 as add-on to Certolizumab Pegol in Subjects With Rheumatoid Arthritis
GlasgowCompleted 2017-04
Efficacy and Safety Study of Ozanimod in Relapsing Multiple Sclerosis
Brighton · Brighton East Sussex · Inverness · London · Romford · SheffieldCompleted 2017-03-27
Efficacy and Safety Study of Ozanimod in Relapsing Multiple Sclerosis
Brighton · Brighton East Sussex · Inverness · London · Romford · SheffieldCompleted 2017-03-27
Efficacy and Safety Study of Ozanimod in Relapsing Multiple Sclerosis
Brighton · Brighton East Sussex · Inverness · London · Romford · SheffieldCompleted 2017-03-27
Efficacy and Safety Study of Ozanimod in Relapsing Multiple Sclerosis
Brighton · Brighton East Sussex · Inverness · London · Romford · SheffieldCompleted 2017-03-27
Clinical Trial to Compare Treatment With GP2017 and Humira® in Patients With Rheumatoid Arthritis
Harlow · LondonCompleted 2017-01-31
ADalimumab in Persistent Early Oligoarthrits Study (ADEOS)
LeedsCompleted 2017-01-16
ADalimumab in Persistent Early Oligoarthrits Study (ADEOS)
LeedsCompleted 2017-01-16
MSB11022 in Moderate to Severe Chronic Plaque Psoriasis
Stoke-on-Trent · DudleyCompleted 2016-12-31
MSB11022 in Moderate to Severe Chronic Plaque Psoriasis
Stoke-on-Trent · DudleyCompleted 2016-12-31
Study of Ozanimod (RPC1063) in Relapsing Multiple Sclerosis (MS)
Cardiff · Inverness · London · SheffieldCompleted 2016-12-22
Study of Ozanimod (RPC1063) in Relapsing Multiple Sclerosis (MS)
Cardiff · Inverness · London · SheffieldCompleted 2016-12-22
Study of Ozanimod (RPC1063) in Relapsing Multiple Sclerosis (MS)
Cardiff · Inverness · London · SheffieldCompleted 2016-12-22
Study of Ozanimod (RPC1063) in Relapsing Multiple Sclerosis (MS)
Cardiff · Inverness · London · SheffieldCompleted 2016-12-22
An Efficacy And Safety Study Evaluating Tofacitinib With And Without Methotrexate Compared To Adalimumab With Methotrexate
Dudley · Cannock · Leeds · Liverpool · LondonCompleted 2016-12
An Efficacy And Safety Study Evaluating Tofacitinib With And Without Methotrexate Compared To Adalimumab With Methotrexate
Dudley · Cannock · Leeds · Liverpool · LondonCompleted 2016-12
An Efficacy And Safety Study Evaluating Tofacitinib With And Without Methotrexate Compared To Adalimumab With Methotrexate
Dudley · Cannock · Leeds · Liverpool · LondonCompleted 2016-12
Long-Term Effectiveness And Safety Of CP-690,550 For The Treatment Of Rheumatoid Arthritis
Dudley · Cannock · Metropolitan Borough of Wirral · Newcastle upon TyneCompleted 2016-11-30
A Single Dose Oral Excretion Balance Study of [14C]-RPC1063 in Healthy Male Adults
NottinghamCompleted 2016-11
A Study Of PF-06410293 (Adalimumab-Pfizer) And Adalimumab (Humira®) In Combination With Methotrexate In Subjects With Active Rheumatoid Arthritis (REFLECTIONS B538-02).
Basingstoke · Metropolitan Borough of Wirral · Bath · LeedsCompleted 2016-08-31
A Study Of PF-06410293 (Adalimumab-Pfizer) And Adalimumab (Humira®) In Combination With Methotrexate In Subjects With Active Rheumatoid Arthritis (REFLECTIONS B538-02).
Basingstoke · Metropolitan Borough of Wirral · Bath · LeedsCompleted 2016-08-31
Efficacy of Secukinumab Compared to Ustekinumab in Patients With Plaque-type Psoriasis
Salford · Dundee · Redhill · Bradford · Coventry · Harrogate · Hull · Stoke-on-TrentCompleted 2016-06-29
Efficacy of Secukinumab Compared to Ustekinumab in Patients With Plaque-type Psoriasis
Salford · Dundee · Redhill · Bradford · Coventry · Harrogate · Hull · Stoke-on-TrentCompleted 2016-06-29
A Study of PF-06438179 (Infliximab-Pfizer) and Infliximab in Combination With Methotrexate in Subjects With Active Rheumatoid Arthritis (REFLECTIONS B537-02).
Wigan · MaidstoneCompleted 2016-06-29
A Study of PF-06438179 (Infliximab-Pfizer) and Infliximab in Combination With Methotrexate in Subjects With Active Rheumatoid Arthritis (REFLECTIONS B537-02).
Wigan · MaidstoneCompleted 2016-06-29
A Study of PF-06438179 (Infliximab-Pfizer) and Infliximab in Combination With Methotrexate in Subjects With Active Rheumatoid Arthritis (REFLECTIONS B537-02).
Wigan · MaidstoneCompleted 2016-06-29
Namilumab vs Adalimumab in Participants With Moderate to Severe Early Rheumatoid Arthritis Inadequately Responding to Methotrexate
London · Salford · OxfordCompleted 2016-06-27
Namilumab vs Adalimumab in Participants With Moderate to Severe Early Rheumatoid Arthritis Inadequately Responding to Methotrexate
London · Salford · OxfordCompleted 2016-06-27
Namilumab vs Adalimumab in Participants With Moderate to Severe Early Rheumatoid Arthritis Inadequately Responding to Methotrexate
London · Salford · OxfordCompleted 2016-06-27
A Long Term Study To Evaluate The Safety And Tolerability Of CP-690,550 For Patients With Moderate To Severe Chronic Plaque Psoriasis
Salford · Nuneaton · London · PeterboroughCompleted 2016-06
A Study Of Oral CP-690,550 As A Maintenance Therapy For Ulcerative Colitis
Cambridge · Bristol · London · Harrow · NorwichCompleted 2016-05-27
Golimumab Utilization and Impact on Ulcerative Colitis (MK-8259-032)
HoddesdonCompleted 2016-05-25
Impact of Natalizumab Versus Fingolimod in Relapsing-Remitting Multiple Sclerosis (RRMS) Participants
London · GlasgowCompleted 2016-05-18
A Study of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque Psoriasis
Dundee · SalfordCompleted 2016-05
Study of Ixekizumab in Participants With Active Ankylosing Spondylitis (AS)
London · Southampton · Norwich · Coventry · Wolverhampton · Bradford · LeedsCompleted 2016-04
Tofacitinib In Psoriatic Arthritis Subjects With Inadequate Response to TNF Inhibitors
Goodmayes · Romford · Dudley · Bradford · Bath · YorkCompleted 2016-04
Efficacy and Safety Study of Certolizumab Pegol (CZP) Versus Active Comparator and Placebo in Subjects With Plaque Psoriasis (PSO)
Dundee · Hexham · Cardiff · Edgbaston · Liverpool · ManchesterCompleted 2016-03-22
Extension Study of MT-1303
City NameCompleted 2016-03
Efficacy and Safety of Sarilumab and Adalimumab Monotherapy in Patients With Rheumatoid Arthritis (SARIL-RA-MONARCH)
LeytonstoneCompleted 2016-01-20
A Study of Guselkumab in Participants With Moderate to Severe Plaque-type Psoriasis and an Inadequate Response to Ustekinumab
Dudley · Dundee · London · SalfordCompleted 2015-12-25
A Study of Guselkumab in Participants With Moderate to Severe Plaque-type Psoriasis and an Inadequate Response to Ustekinumab
Dudley · Dundee · London · SalfordCompleted 2015-12-25
Efficacy And Safety Of Tofacitinib In Psoriatic Arthritis: Comparator Study
Goodmayes · Romford · Dudley · Bradford · Upton · YorkCompleted 2015-12-18
Efficacy And Safety Of Tofacitinib In Psoriatic Arthritis: Comparator Study
Goodmayes · Romford · Dudley · Bradford · Upton · YorkCompleted 2015-12-18
SWITCH Clinical Trial for Patients With Rheumatoid Arthritis Who Have Failed an Initial TNF-blocking Drug.
LeedsCompleted 2015-11
SWITCH Clinical Trial for Patients With Rheumatoid Arthritis Who Have Failed an Initial TNF-blocking Drug.
LeedsCompleted 2015-11
SWITCH Clinical Trial for Patients With Rheumatoid Arthritis Who Have Failed an Initial TNF-blocking Drug.
LeedsCompleted 2015-11
SWITCH Clinical Trial for Patients With Rheumatoid Arthritis Who Have Failed an Initial TNF-blocking Drug.
LeedsCompleted 2015-11
SWITCH Clinical Trial for Patients With Rheumatoid Arthritis Who Have Failed an Initial TNF-blocking Drug.
LeedsCompleted 2015-11
SWITCH Clinical Trial for Patients With Rheumatoid Arthritis Who Have Failed an Initial TNF-blocking Drug.
LeedsCompleted 2015-11
Study to Assess the Short- and Long-term Efficacy of Certolizumab Pegol Plus Methotrexate Compared to Adalimumab Plus Methotrexate in Subjects With Moderate to Severe Rheumatoid Arthritis (RA) Inadequately Responding to Methotrexate
Ashford · Brighton · Leeds · London · Poole · Sheffield · Upton · WiganCompleted 2015-11
Study to Assess the Short- and Long-term Efficacy of Certolizumab Pegol Plus Methotrexate Compared to Adalimumab Plus Methotrexate in Subjects With Moderate to Severe Rheumatoid Arthritis (RA) Inadequately Responding to Methotrexate
Ashford · Brighton · Leeds · London · Poole · Sheffield · Upton · WiganCompleted 2015-11
Study to Assess the Short- and Long-term Efficacy of Certolizumab Pegol Plus Methotrexate Compared to Adalimumab Plus Methotrexate in Subjects With Moderate to Severe Rheumatoid Arthritis (RA) Inadequately Responding to Methotrexate
Ashford · Brighton · Leeds · London · Poole · Sheffield · Upton · WiganCompleted 2015-11
Efficacy and Safety of GLPG0634 in Subjects With Active Crohn's Disease
Birmingham · Bournemouth · Harrow · ManchesterCompleted 2015-11
A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Participants With Secondary Progressive Multiple Sclerosis
Irvine · Edgbaston · Exeter · Plymouth · London · Hammersmith · Edinburgh · Salford · Liverpool · Norwich · Nottingham · Morriston · Newcastle · Brighton · SheffieldCompleted 2015-07-28
A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drugs (DMARD)-naïve Adults With Early Active Rheumatoid Arthritis
Cannock · Dudley · Leeds · London · Sheffield · YorkCompleted 2015-07
A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drugs (DMARD)-naïve Adults With Early Active Rheumatoid Arthritis
Cannock · Dudley · Leeds · London · Sheffield · YorkCompleted 2015-07
A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)
Birmingham · Brighton · Bristol · Cambridge · Cardiff · Exeter · Gloucester · Liverpool · London · Manchester · Norwich · Nottinghamshirecc · Oxford · Shropshire · SouthamptonCompleted 2015-06-10
A Study To Evaluate Both The Efficacy and Safety Profile of CP-690,550 In Patients With Moderately to Severely Active Ulcerative Colitis
Bristol · Harrow · NorwichCompleted 2015-05
A Study Evaluating The Efficacy And Safety Of CP-690,550 In Patients With Moderate To Severe Ulcerative Colitis
Cambridge · LondonCompleted 2015-05
A Study in Moderate to Severe Rheumatoid Arthritis
London · Basingstoke · Southampton · Aberdeen · North Shields · BradfordCompleted 2015-03
A Study in Moderate to Severe Rheumatoid Arthritis
London · Basingstoke · Southampton · Aberdeen · North Shields · BradfordCompleted 2015-03
Comparative Oral Bioavailability Study of MT-1303
LeedsCompleted 2015-03
An Evaluation of Sarilumab Plus Methotrexate Compared to Etanercept Plus Methotrexate in RA Patients Not Responding to Adalimumab Plus Methotrexate
Barnsley · Birmingham · Dudley · Durham · Harlow · WiganCompleted 2015-01
An Evaluation of Sarilumab Plus Methotrexate Compared to Etanercept Plus Methotrexate in RA Patients Not Responding to Adalimumab Plus Methotrexate
Barnsley · Birmingham · Dudley · Durham · Harlow · WiganCompleted 2015-01
Optimal Management of Rheumatoid Arthritis Patients Requiring Biologic Therapy
Widygates · Wishaw · Aberdeen · Dundee · Edinburgh · Glasgow · Inverness · MelroseCompleted 2014-12
Optimal Management of Rheumatoid Arthritis Patients Requiring Biologic Therapy
Widygates · Wishaw · Aberdeen · Dundee · Edinburgh · Glasgow · Inverness · MelroseCompleted 2014-12
A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence
Cambridge · Cardiff · London · Manchester · Norwich · Nottinghamshirecc · OxfordCompleted 2014-12
A Study of Ixekizumab in Participants With Active Psoriatic Arthritis
Cambridge · Goodmayes · London · Headington · Wolverhampton · Bradford · Leeds · LiverpoolCompleted 2014-12
Bioavailability and Pharmacokinetics of Vedolizumab in Healthy Participants Following Single Subcutaneous Administration
LondonCompleted 2014-12
A Phase 1 Study to Explore the Cardiac Pharmacodynamics of MT-1303
LeedsCompleted 2014-12
Mass Balance Study of MT-1303
RuddingtonCompleted 2014-12
A Study of Mavrilimumab Versus Anti Tumor Necrosis Factor in Subjects With Rheumatoid Arthritis
Birkenhead · Cambridge · Edinburgh · London · PlymouthCompleted 2014-11
Efficacy and Safety Study of ABP 501 Compared to Adalimumab in Subjects With Moderate to Severe Rheumatoid Arthritis
Barnsley · North Shields · Suffolk · CardiffCompleted 2014-11
Multiple Ascending Dose Study of GLPG0634 in Japanese and Caucasian Healthy Subjects
LondonCompleted 2014-09
A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)
Birmingham · Brighton · Bristol · Cambridge · Gloucester · Harrow · Liverpool · London · Manchester · Norwich · Nottinghamshirecc · Oxford · Shrewsbury · SouthamptonCompleted 2014-08
A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drugs (DMARD)-naïve Adults With Early Active Rheumatoid Arthritis
Cannock · Dudley · Leeds · London · Sheffield · YorkCompleted 2014-07
A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drugs (DMARD)-naïve Adults With Early Active Rheumatoid Arthritis
Cannock · Dudley · Leeds · London · Sheffield · YorkCompleted 2014-07
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of MT-1303 in Subjects With Inflammatory Bowel Disease
NottinghamCompleted 2014-07
Dose-finding Study of MT-1303
LondonCompleted 2014-07
A Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability, Immunogenicity, and Pharmacodynamics (PD) of GSK2800528 in Healthy Subjects.
LondonCompleted 2014-04-03
Natalizumab (Tysabri) Re-Initiation of Dosing
Essex · Liverpool · London · Newcastle upon Tyne · Oxford · Sheffield · Stoke-on-TrentCompleted 2014-04
Single Rising Dose Study of BI 655066 in Patients With Moderate and Severe Psoriasis
LeedsCompleted 2013-10
Golimumab in Rheumatoid Arthritis Participants With an Inadequate Response to Etanercept (ENBREL) or Adalimumab (HUMIRA)
Cannock · Leeds · London · Manchester · Merseyside · Newcastle upon Tyne · WiganCompleted 2013-07
Golimumab in Rheumatoid Arthritis Participants With an Inadequate Response to Etanercept (ENBREL) or Adalimumab (HUMIRA)
Cannock · Leeds · London · Manchester · Merseyside · Newcastle upon Tyne · WiganCompleted 2013-07
Golimumab in Rheumatoid Arthritis Participants With an Inadequate Response to Etanercept (ENBREL) or Adalimumab (HUMIRA)
Cannock · Leeds · London · Manchester · Merseyside · Newcastle upon Tyne · WiganCompleted 2013-07
Randomised Double-Blind, Placebo-Controlled, Parallel Group Study in Patients With Active Rheumatoid Arthritis:Magnetic Resonance Imaging Sub-Study
Manchester · OxfordCompleted 2013-07
A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)
Birmingham · Brighton · Bristol · Cambridge · Cardiff · Exeter · Gloucester · Harrow · Liverpool · London · Manchester · Norwich · Nottinghamshirecc · Oxford · Shropshire · South Shields · SouthamptonCompleted 2013-06
Investigation of the Pharmacokinetics and Metabolism of GLPG0634 in Healthy Male Subjects
NottinghamCompleted 2013-04
A Study of the Safety and Efficacy of Ustekinumab in Adolescent Patients With Psoriasis (CADMUS)
Cardiff · London · YorkCompleted 2013-01
A Study To Evaluate The Effects And Safety Of Treatment, Treatment Withdrawal, Followed By Re-Treatment With CP-690,550 In Subjects With Moderate To Severe Chronic Plaque Psoriasis
London · Nuneaton · ManchesterCompleted 2013-01
A Phase 3, Multi Site, Randomized, Double Blind, Placebo Controlled Study Of The Efficacy And Safety Comparing CP- 690,550 And Etanercept In Subjects With Moderate To Severe Chronic Plaque Psoriasis
London · LeicesterCompleted 2013-01
Evaluation of Efficacy and Safety of Fostamatinib Monotherapy Compared With Adalimumab Monotherapy in Patients With Rheumatoid Arthritis (RA)
Reading · London · Eastbourne · Basingstoke · Manchester · WolverhamptonCompleted 2012-10
A Study to Evaluate the Safety and Effectiveness of Ustekinumab or Golimumab Administered Subcutaneously (SC) in Patients With Sarcoidosis
Bristol · London · Portsmouth · Sheffield · SouthamptonCompleted 2012-05
A Study to Evaluate the Safety and Effectiveness of Ustekinumab or Golimumab Administered Subcutaneously (SC) in Patients With Sarcoidosis
Bristol · London · Portsmouth · Sheffield · SouthamptonCompleted 2012-05
Immune Response to Systemic and Mucosal Antigenic Challenge in the Presence of Vedolizumab
ManchesterCompleted 2012-05
A Study of the Safety and Efficacy of Ustekinumab in Patients With Psoriatic Arthritis With and Without Prior Exposure to Anti-TNF Agents
Cannock · Glasgow · London · Metropolitan Borough of Wirral · Newcastle upon Tyne · Salford · Sheffield · Southampton · Westcliff-on-Sea · WiganCompleted 2012-03
A Study of Tocilizumab (RoActemra/Actemra) Versus Adalimumab in Patients With Rheumatoid Arthritis
Cannock · Leeds · London · Newcastle upon Tyne · PooleCompleted 2012-01
Certolizumab Pegol in Subjects With Adult Onset Active and Progressive Psoriatic Arthritis
Barnsley · London · SalfordCompleted 2011-11
A Study of the Safety and Effectiveness of Ustekinumab in Patients With Psoriatic Arthritis
Cannock · Glasgow · London · Metropolitan Borough of Wirral · Salford · WiganCompleted 2011-10
Certolizumab Pegol in Subjects With Active Axial Spondyloarthritis
Barnsley · Leeds · London · SalfordCompleted 2011-10
Seronegative Oligoarthritis of the Knee Study (SOKS)
LeedsCompleted 2011-08
Seronegative Oligoarthritis of the Knee Study (SOKS)
LeedsCompleted 2011-08
The HAM Infliximab Study
LondonCompleted 2011-03
A Phase 3 Study Comparing 2 Doses Of CP-690,550 And The Active Comparator, Humira (Adalimumab) Vs. Placebo For Treatment Of Rheumatoid Arthritis
Metropolitan Borough of Wirral · Cannock · Dudley · West MidlandsCompleted 2011-03
A Phase 3 Study Comparing 2 Doses Of CP-690,550 And The Active Comparator, Humira (Adalimumab) Vs. Placebo For Treatment Of Rheumatoid Arthritis
Metropolitan Borough of Wirral · Cannock · Dudley · West MidlandsCompleted 2011-03
Open Label Long-Term Safety Study of Certolizumab Pegol (CZP) for Patients With Rheumatoid Arthritis
Birmingham · Cannock · Colchester · Glasgow · Harrogate · London · Manchester · Metropolitan Borough of Wirral · Oxford · PeterboroughCompleted 2011-02
Study of Adalimumab in Patients With Axial Spondyloarthritis
Newcastle upon TyneCompleted 2011-02
Infliximab as Induction Therapy in Early Rheumatoid Arthritis (IDEA)
LeedsCompleted 2011-02
Infliximab as Induction Therapy in Early Rheumatoid Arthritis (IDEA)
LeedsCompleted 2011-02
Infliximab as Induction Therapy in Early Rheumatoid Arthritis (IDEA)
LeedsCompleted 2011-02
Infliximab as Induction Therapy in Early Rheumatoid Arthritis (IDEA)
LeedsCompleted 2011-02
A Study Comparing 2 Doses Of CP-690,550 Vs. Placebo For The Treatment Of Rheumatoid Arthritis In Patients On Other Background Arthritis Medications
Metropolitan Borough of Wirral · Cannock · Solihull · Newcastle upon TyneCompleted 2011-01
Examination of Radiographic Progression, Efficacy and Safety of Long-Term Treatment With Infliximab in Patients With Ankylosing Spondylitis
Cambridge · LeedsCompleted 2010-11
A Safety and Efficacy Study of Ustekinumab in Patients With Plaque Psoriasis Who Have Had an Inadequate Response to Methotrexate
Aberdeen · Cardiff · Craigavon · Glasgow · London · Nottingham · SalfordCompleted 2010-11
A Safety and Efficacy Study of Ustekinumab in Patients With Plaque Psoriasis Who Have Had an Inadequate Response to Methotrexate
Aberdeen · Cardiff · Craigavon · Glasgow · London · Nottingham · SalfordCompleted 2010-11
Study of the Optimal Protocol for Methotrexate and Adalimumab Combination Therapy in Early Rheumatoid Arthritis
Bath · Huddersfield · Leeds · London · Newcastle upon Tyne · Oxford · Southampton · YorkCompleted 2010-07
Study of the Optimal Protocol for Methotrexate and Adalimumab Combination Therapy in Early Rheumatoid Arthritis
Bath · Huddersfield · Leeds · London · Newcastle upon Tyne · Oxford · Southampton · YorkCompleted 2010-07
Efficacy and Safety of Adalimumab in Pediatric Subjects With Moderate to Severe Crohn's Disease
LondonCompleted 2010-05
A Study of Safety and Effectiveness of Ustekinumab in Patients With Moderate to Severe Active Crohn's Disease Who Have Been Previously Treated With Anti-TNF Therapy
Bristol · Cambridge · Coventry · Edinburgh · Harrow · London · Manchester · Newcastle upon Tyne · Norwich · NottinghamshireccCompleted 2010-05
Follow-up to Welcome Study C87042 [NCT00308581] Examining Certolizumab Pegol (CDP870) in Subjects With Crohn's Disease
Bristol · London · OxfordCompleted 2010-04
RESTART C0168Z05 Rheumatoid Arthritis Study
Leeds · London · WiganCompleted 2010-01
A Study to Investigate the Safety and Efficacy of CP-690,550 in Patients With Moderate to Severe Crohn's Disease
Bristol · SalfordCompleted 2009-10
Study Comparing 80 mg of Adalimumab With Placebo, and Demonstrating the Non-inferiority of Monthly 80 mg Adalimumab Dosing Compared With 40 mg Adalimumab Every Other Week Dosing
Metropolitan Borough of Wirral · Liverpool · Oxford · Bath · Cannock · Newcastle upon Tyne · Leeds · HuddersfieldCompleted 2009-04
Efficacy and Safety of Adult Human Mesenchymal Stem Cells to Treat Steroid Refractory Acute Graft Versus Host Disease (GVHD)
London · Headington · Bristol · Glasgow · LeedsCompleted 2008-12-26
Adalimumab in Combination With Topical Treatment (Calcipotriol/Betamethasone) in Subjects With Moderate to Severe Psoriasis and Insufficient Response to Classic Systemic Treatment
Aberdeen · Cardiff · Glasgow · Leeds · London · Manchester · Newport Gwent · NuneatonCompleted 2008-10
Study of Adalimumab Treatment for Induction and Maintenance of Clinical Remission in Subjects With Crohn's Disease
Barnstaple · Cardiff · Dundee · Edinburgh · Harrow · Liverpool · London · Nottingham · Plymouth · Portsmouth · Rotherham · Sheffield · Southampton · Stockport · SurreyCompleted 2008-07
Trial Comparing Infliximab and Infliximab and Azathioprine in the Treatment of Patients With Crohn's Disease na�ve to Both Immunomodulators and Biologic Therapy (Study of Biologic and Immunomodulator Naive Patients in Chrohn's Disease: SONIC
Bristol · Cambridge · Leeds · Livingston · London · Newcastle upon Tyne · StockportCompleted 2008-04
Trial Comparing Infliximab and Infliximab and Azathioprine in the Treatment of Patients With Crohn's Disease na�ve to Both Immunomodulators and Biologic Therapy (Study of Biologic and Immunomodulator Naive Patients in Chrohn's Disease: SONIC
Bristol · Cambridge · Leeds · Livingston · London · Newcastle upon Tyne · StockportCompleted 2008-04
A Study of the Safety and Efficacy of Golimumab in Subjects With Rheumatoid Arthritis That Are Methotrexate-naive
Leeds · LondonCompleted 2008-04
A Study of the Safety and Efficacy of Golimumab in Subjects With Rheumatoid Arthritis That Are Methotrexate-naive
Leeds · LondonCompleted 2008-04
Certolizumab in Crohn's Disease Patients With Loss of Response or Intolerance to Infliximab
Bristol · Cambridge · Edinburgh · London · Nottingham · Oxford · SheffieldCompleted 2008-04
Certolizumab in Crohn's Disease Patients With Loss of Response or Intolerance to Infliximab
Bristol · Cambridge · Edinburgh · London · Nottingham · Oxford · SheffieldCompleted 2008-04
A Study of the Safety and Efficacy of Golimumab (CNTO 148) in Subjects With Active Rheumatoid Arthritis Previously Treated With Biologic Anti-TNFa Agent(s)
Leeds · London · OxfordCompleted 2007-08
A Study of Safety and Efficacy of CNTO 148 in Patients With Severe Persistent Asthma
Glasgow · SouthamptonCompleted 2007-07
A Study of the Safety and Efficacy of Golimumab in Patients With Active Psoriatic Arthritis
Glasgow · London · Middlesbrough · WiganCompleted 2007-05
A Study of the Safety and Efficacy of Ustekinumab (CNTO 1275) in Patients With Moderate to Severe Psoriasis
London · Salford · Southampton Trials Carried OutCompleted 2006-12
Anti-Cytokine Therapy for Vasculitis
BirminghamCompleted 2006-07
Anti-Cytokine Therapy for Vasculitis
BirminghamCompleted 2006-07
Long-term Safety and Tolerability Study of Adalimumab in Subjects With Crohn's Disease
Edinburgh · RotherhamCompleted 2006-03
Safety and Efficacy of Natalizumab in the Treatment of Multiple Sclerosis
Queen Square · Whitechapel · Wimbledon · Essex · Ipswich · Leeds · London · Newcastle upon Tyne · Oxford · Sheffield · Stoke-on-TrentCompleted 2004-11
Safety, Tolerability and Effectiveness of Natalizumab in Adolescents With Active Crohn's Disease
Edinburgh · LondonCompleted 2004-05
Efficacy and Safety of Adalimumab and Methotrexate (MTX) Versus MTX Monotherapy in Subjects With Early Rheumatoid Arthritis
Bangor · Cambridge · Hereford · Leeds · London · Newcastle upon TyneCompleted 2004-04
Efficacy and Safety of Adalimumab and Methotrexate (MTX) Versus MTX Monotherapy in Subjects With Early Rheumatoid Arthritis
Bangor · Cambridge · Hereford · Leeds · London · Newcastle upon TyneCompleted 2004-04
An Open-Label Study to Evaluate the Response to Adalimumab in Patients With Active Ankylosing Spondylitis Who Have Failed Standard Therapy or TNF-Alpha Inhibitors (RHAPSODY)
Aberdeen · Avon · Birmingham · Cambridge · Greater Manchester · Harrow · Huddersfield · Leeds · Liverpool · London · Merseyside · Newcastle upon Tyne · Oxford · Portsmouth · Sheffield · Southampton · Truro · Wigan
Trial participation is subject to strict clinical inclusion and exclusion criteria determined by hospital investigator teams. Patients should discuss potential study participation with their NHS gastroenterologist.
How UK Drug Approval & NHS Access Works
The Medicines and Healthcare products Regulatory Agency (MHRA) evaluates whether a medicine is safe and clinically effective. An MHRA licence makes a medicine legal to prescribe in the UK.
The National Institute for Health and Care Excellence (NICE) assesses clinical and cost-effectiveness. A positive NICE appraisal mandates that NHS England and Wales fund the medicine for eligible patients.
Why is an approved medicine not always funded on the NHS?
A medicine can receive regulatory marketing authorisation from the MHRA (or previously the EMA) based purely on clinical safety and efficacy, but NICE may determine that its price does not represent sufficient value for money compared to existing standard NHS therapies. In other cases, NICE approves a medicine only after conventional treatments or earlier biologics (like anti-TNF inhibitors) have failed or cannot be tolerated.
How does NHS access differ in Scotland, Wales, and Northern Ireland?
NICE recommendations apply directly to NHS England and are routinely adopted by NHS Wales. NHS Scotland evaluates medicines independently through the Scottish Medicines Consortium (SMC). Northern Ireland's Department of Health typically reviews NICE decisions for local implementation.